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INTRODUCTION 
Morphoea is an uncommon benign fibrosing disease which shows 
involvement of dermis, subcutaneous fat and underlying tissues, more 
prevalent in females, and is a separate disorder from systemic sclerosis as 
there is no internal organ involvement. 
 Morphoea causes fibrosis of all mesoderm derived tissues and rarely, 
the central nervous system [CNS]. Linear, generalized, and pansclerotic types 
are associated with morbid features like contractures, facial disfigurement, 
distress, arthralgia and CNS involvement. 
 
 The pathogenesis of morphoea is still an enigma, but is proposed to be 
started by injury to the vessels that results in increased collagen synthesis and 
diminished collagen destruction. There are interesting serological 
associations with morphoea also. Various other systemic and cutaneous 
diseases have also been found to be associated with morphoea. 
 
This disease often progresses for several years and then regresses even 
without treatment although various modalities of treatment have been tried in 
the past. 
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REVIEW OF LITERATURE 
  
 
SYNONYMS 
Localized scleroderma, Circumscribed scleroderma, Scleroderma en coup de 
sabre 
 
HISTORICAL ASPECTS 
 
The word morphoea was first used by Erasmus Wilson to describe this 
disease as he felt that the areas were vestiges of true leprosy
1
. Morphoea has 
been derived from „morpheus‟ who in Greek tradition is considered as god of 
dreams with the capability to acquire any human form and appear in dreams.  
 
The term „sclerodermie‟ was coined in 1847 by the French physician, 
Gintrac
2
.  
 
Thomas Addison came up with the first detailed report on morphoea, 
who differentiated a „„true keloid‟‟ from a „„keloid of Alibert.‟ The entity 
described by Alibert is now called as a keloid
3
. Matsui
4
 described the typical 
histopathological changes of scleroderma in 1924. O‟Leary and Nomland5 
elaborated the distinctive features of systemic sclerosis versus morphoea in 
an extensive clinical study in 1930. 
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DEFINITION 
 
 
Morphoea is a localized form of scleroderma with increased collagen 
deposition leading to sclerosis of the dermis and underlying tissues
6
. It is a 
disorder of unknown cause with many clinical types and lack of systemic 
involvement thereby differentiating it from systemic sclerosis
7
.  
 
 
CLASSIFICATION OF MORPHOEA 
 
Schachter
8
 in 1989 subdivided localized scleroderma into 
   
1) Morphoea- Limited (Plaque or Guttate), Generalised and others  
 
                   (subcutaneous, nodular). 
 
2) Linear scleroderma- Linear or en coup de sabre. Since this scheme proved 
to be inconclusive, another classification was  proposed by Peterson et al
9
 
in 1995 which divided morphoea into five main types 
 
   
1) PLAQUE MORPHOEA 
 
Morphoea en plaque  
 
Guttate morphoea 
 
Atrophoderma of Pasini and Pierini 
 
Keloid morphoea (nodular morphoea) 
 
[Lichen sclerosus et atrophicus {LSA}] 
 
 
 
 
 
10 
 
2) GENERALIZED MORPHOEA 
 
3) BULLOUS MORPHOEA 
 
4) LINEAR MORPHOEA 
 
Linear morphoea  
 
En coup de sabre (ECDS) 
 
Progressive hemifacial atrophy 
 
5) DEEP MORPHOEA 
 
Subcutaneous morphoea 
 
Eosinophilic fasciitis 
 
Morphoea profunda 
 
Disabling pansclerotic morphoea of childhood 
 
 
 
This classification is questioned now because of two main reasons. 
Firstly, it has many entities which are not universally considered under 
morphoea like LSA, Pasini and Pierini‟s atrophoderma and eosinophilic 
fasciitis. Secondly, it does not include those patients who have more than one 
morphological type of morphoea and can be considered under an entity, 
„mixed‟ variant. 
 
Recently, a new classification for localized scleroderma was proposed at 
consensus conference at Padua, Italy in 2004, which included circumscribed  
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morphoea, linear morphoea, pansclerotic morphoea, generalized morphoea 
and mixed morphoea
10
. 
 
Types      Subtypes   Details 
 
Circumscribed 
morphoea    
Superficial     
 
 
 
 
 
Deep                   
Single or multiple, oval or round 
indurated areas involving epidermis and 
dermis often with a surrounding liliac 
ring.    
                                                                       
 
Single or multiple oval or round deeply 
indurated areas involving subcutaneous 
(SC) tissue (upto muscle in few cases); 
may spare the skin above.                                                                                                                                                                       
Linear morphoea       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
Trunk/limb 
subtype   
 
 
 
 
Head subtype 
 
     
 
 
 
 
Indurated areas in a linear fashion 
involving the dermis and SC tissue (may 
involve upto the level of muscle and 
bone)  
                                                                                  
                                                                               
 En coup de sabre           
                                                                            
Induration in a linear fashion of the face 
and scalp (can include muscle, bone and 
CNS)                                          
                                                                                 
  
Parry Romberg syndrome (PRS) 
 
Involvement of one side of the face with 
overlying mobile skin.                                                                                                                                                                                                             
Generalized 
morphoea 
 Individual indurated plaques, 4 or more 
in number, of size more than 3 cm each 
and involving two of seven sites  
including head and neck, front of trunk, 
back of trunk, right upper limb, left 
upper limb, right lower limb, left lower 
limb.                                                                                                                           
 
 
12 
 
Pansclerotic 
morphoea    
 Circumferential involvement of limbs 
upto the level of bones. Other body 
areas may also be affected. 
Mixed variant 
morphoea          
 Variant with 2 or more of the above 
mentioned subtypes. Sequence is 
consistent with predominant 
representation in the patient like 
(pansclerotic-circumscribed). 
 
 
 
 
 
EPIDEMIOLOGY OF MORPHOEA 
 
 
Morphoea can affect all ages though it is most commonly seen in the 
20- 40 years age group, but the disease commences before the age of 10 years 
in 15 %  of cases according to a study conducted by Christianson et al
11
 on 
235 cases. The extremes of age were 1 year and 76 years in this study
11
. 
 The prevalence of the disease also increases with age
12
. It is 
undoubtedly more common in females with ratio approximately being 3:1 in 
most studies
11,12
 with the exception of linear  morphoea which has no gender 
preference
 
. In a study done by Peterson et al
12
 in Olmsted county between 
1960-1993 on 82 cases showed the incidence rate as 27 per million 
population. According to the same study
12
, 56% of patients had  plaque type 
morphoea, 20% linear, 13% generalized and 11% deep morphoea whereas 
study conducted by Christianson et al
11
 showed more number of cases  with 
linear morphoea as compared to plaque type.  
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           A worldwide study of 750 children with juvenile localized 
scleroderma also reported more percentage of linear lesions than plaques
13
. 
Also, Christianson‟s study11 showed that linear lesions appeared before the  
age of 10 years in 20%  and prior to the age of 40 in 75%  but plaque lesions 
appeared  later in life, 10%  were seen prior to the age of 10 years and 75% 
becoming evident between the ages of 20 and 50. The results from these 
studies show that linear morphoea is more commonly seen in children as 
compared to adults. 
 
          Morphoea is more prevalent in Caucasians and Asians and it has been 
reported to be rare in black people like African Americans
14,15
. The disease is 
active for a span of 3 to 6 years on an average
15,16
. Relapses are more 
commonly seen in patients with generalized morphoea, linear morphoea and 
deep morphoea whereas circumscribed morphoea has the shortest course
16
. 
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AETIOLOGY 
 
1) TRAUMA 
 
Trauma can be considered as a triggering factor for morphoea 
and may precede the onset of the disease by many months
17
. Two case 
reports suggesting that trauma causes an isomorphic response and 
appearance of new typical lesions in known cases of morphoea have 
been published
18
. The mechanism is still unknown but local production 
and dysregulation of inflammatory mediators including fibrogenic 
cytokines such as transforming growth factor (TGF-β) have been 
proposed to cause excessive synthesis of collagen
19
. Trauma has been 
reported as a precipitating factor in approximately 13% of the children 
examined under two large studies of almost 900 cases
13, 20
. The study 
conducted by Christianson et al
11
 reported 14 cases out of 191 with 
trauma as the preceding factor. 
 
 
2) IMMOBILIZATION 
 
Immobilization is another aetiological factor proposed for 
morphoea. It has been reported that it causes dermal fibroblasts 
activation, thereby releasing inflammatory cells and ultimately causes 
fibrosis
21
. 2 cases have been reported till date which developed 
morphoea after immobilization
21
. 
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3) VACCINATIONS AND INJECTIONS 
 
Vaccinations such as B.C.G , D.P.T, MMR
 
, tetanus
 
and hepatitis B
 
 
have been reported to cause morphoea
22,23,24
. The underlying pathogenesis 
is still not well understood; it has been proposed that injection trauma 
causes endothelial injury and hypoxia of tissues which leads on to 
morphoea. Another hypothesis proposed is that vaccines induce an 
immune response against various antigens (specific as well as 
nonspecific). Finally, wound healing releases various cytokines and 
growth factors which might also predispose to trauma induced morphoea. 
Till date, 8 cases of vaccination induced morphoea have been reported
25
. 
 
Other injections like vitamin K, vitamin B12 and progesterone have 
also been reported as causative factors for morphoea
22,26
. The vehicle 
used, the preservative, and hypersensitivity have been implicated as the          
various reasons behind this
26
. There have been many case reports of        
morphoea developing after vitamin K injections (Texier disease) and it 
has been observed that it takes 1 month to almost 2 years for the 
morphoea like changes to occur
27
. High dosing is another factor which 
was seen in most of the cases. These sclerodermoid plaques were called as 
„cowboy‟s belt with revolver‟ in one recent case report
28
. 
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4) RADIOTHERAPY 
 
`  Morphoea has been reported to occur following radiotherapy, 
most commonly seen in women with breast carcinoma
29
. The incidence 
has been reported to be 1 in 500 cases
29
. The morphoea lesions usually 
develop around the irradiation port but some cases show involvement of 
areas beyond these sites or may extend to any other distal site
29
. The time 
duration after which the patient develops such lesions ranges from less 
than 1 year to 32 years after irradiation
29
. The pathogenesis proposed 
involves either activation of fibroblasts or self antigen presentation 
resulting in tissue damage
25
. Another case with post-fluoroscopy 
appearance of morphoea was also reported
30
. 
 
5) SURGICAL OPERATIONS 
 
Surgical operations have been known to precede morphoea. 
Surgeries like rhinoplasty and AV fistula formation have been reported 
to cause morphoea. Another case report stated the development of 
morphoea post-laparotomy
22
. 
 
6) HORMONAL FACTORS 
 
There are case reports where pregnancy has been reported to 
exacerbate lesions of morphoea
31
. A recent case report published in 
2011 described pregnancy exacerbation of en coup de sabre and post 
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partum development of rheumatoid arthritis
31
. The mechanism 
proposed for this association deals with increase in the number of T 
regulatory cells in pregnancy which causes increased synthesis of 
TGF-β which is a known potent pro-fibrogenic mediator in 
scleroderma. A higher incidence of morphoea has also been seen 
around menarche. Parathormone has also been linked with morphoea 
by causing calcium deposition in soft tissues
14
 and subtotal 
parathyroidectomy has been used as the treatment but no real proof has 
been offered to support this. Leriche and co-workers
32
 observed 13 
patients with generalized scleroderma for 2 to 5 years after a subtotal 
parathyroidectomy with 90% improvement.  
 
7) INFECTIONS 
 
Borrelial infection has also been proposed to play a role in 
morphoea. After reviewing various studies on borrelial infection in 
morphoea, it was concluded that about 51% of patients were reported 
to have been infected with Borrelia infection
25
. Even, histopathological 
specimens of morphoea patients have revealed borrelial DNA in few 
cases
33
. On the other hand, various other studies have reported 
contradicting findings stating that there is no association between 
morphoea and Borrelia infection
34
.  
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The probable reason for almost all the reports coming from 
Europe might be the difference in strains seen in Europe in 
comparision to United States of America (B.afzelii or B.garinii vs 
B.burgdorferi sensu stricto, respectively)
25
. Reports proposing 
Cytomegalovirus as another aetiologic agent have also been 
published
35
. Morphoea has been reported to follow infections like 
varicella, herpes zoster, toxoplasmosis and hepatitis C as well
22,36,37
. 
 
8) GENETIC FACTORS 
 
Genetic role for morphoea is still unclear but a familial incidence 
has been noted and there have been reports of localized scleroderma 
occurring in monozygotic twins
38
. There has been no significant HLA 
association reported with morphoea till date
39
. Organ specific 
autoantibodies have also shown a rise in some patients and relatives
22
. 
 
9) ROLE OF DRUGS 
 
There have been reports of morphoea occuring after intake of 
various drugs such as D-penicillamine, bromocriptine, hydroxytryptophan, 
carbidopa, valproic acid, pentazocine, docetaxel, paclitaxel, bleomycin 
and after melphalan limb perfusion
22
. Other drugs like bisoprolol, 
peplomycin and balicatib have also been implicated in development of 
morphoea
40
. The onset of morphoea after starting the drug ranges from 1 
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month to 30 months
40
. Withdrawal of drugs may or may not result in 
clearance of lesions.  
Kraigher et al
41
 documented blaschkoid unilateral generalized 
morphoea after intake of ibuprofen which showed relief after stopping the 
drug. The pathogenesis mainly revolves around production of 
autoantibodies by these drugs that affect the microvasculature and 
ultimately forming morphoea plaques
25
. 
 
10) OTHER MISCELLANEOUS CAUSES 
 
Other triggering factors include mechanical compression from 
clothing, pigmented purpuric dermatosis like lichen aureus
42
. Even 
exposure to epoxy resins, vinyl chloride, organic solvents and pesticides, 
silicon implants etc have been reported to produce scleroderma like 
changes. 
 
 
PATHOGENESIS 
 
An increase in extracellular matrix and collagen deposition mainly 
accounts for the pathogenesis of morphoea. The exact mechanism for this 
still remains an enigma. Pathogenesis can be understood under the following 
headings 
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a) VASCULAR INJURY 
     
 
According to the vascular theory, morphoea starts with an injury to the 
vessels which may be caused by an infection or antibodies to endothelial 
cells
43
. This is further supported by the biopsy changes seen in the early  
morphoea lesions. 
 
b) ADHESION MOLECULES EXPRESSION AND PRO FIBROTIC  
 
     CYTOKINES SYNTHESIS 
 
The injury to the endothelium leads to cytokine release which causes 
increased intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and E-selectin expression
44
. These molecules via T 
cells release other cytokines which cause fibrosis like IL- 4, IL-6 and TGF-β. 
This leads to accumulation of eosinophils, helper T cells, and macrophages. 
These cells are thought to present self antigens to the immune system of the 
body and thereby release autoantibodies.  
 
Various chemokines such as CCL and CXCL8 have also been proposed to be 
involved in the pathogenesis of fibrosis
45
. Other cytokines like IL-2 receptor, 
CD 23, CD30 and B-cell activating factor also play a role
22
.                            
The stage of active inflammation and sclerosis has shown the presence of CD 
34 and dermal dendrocytes. Sclerodermatous skin has been reported to show 
mast cells in the early stages
46
. 
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c) OVERABUNDANCE OF COLLAGEN DEPOSITION 
   
Upregulation of TGF-β leads to collagen, fibronectin, and proteoglycan 
deposition and it also diminishes collagen degradation by causing a decline in 
the levels of matrix metalloproteinases
45,47
. This variation in the amount of 
collagen deposition and collagen degradation is the proposed mechanism of 
the fibrosis seen in morphoea
47
. Antibodies to MMP‟s may also play a role in 
the inhibition of collagen degradation. The accumulation of myofibroblasts  
by GTPase Rac 1 also plays a role in the pathogenesis
48
. Insulin-like growth 
factor may also contribute to the development of morphoea by accumulating 
fibroblasts and increasing collagen and extracellular matrix deposition
49
.  
Gene array analyses showed 4 separate gene signatures and were 
classified as inflammatory, limited, proliferative and normal-like. The 
inflammatory signature was seen in patients with morphoea. Other signatures 
were seen in systemic sclerosis
50
.           
 
ROLE OF MICROCHIMERISM 
 
          There has been a recent advancement in the understanding of 
morphoea and scleroderma with microchimerism being proposed to play a 
role. Various PCR studies (realtime and nested) have shown the presence of 
chimeric cells in morphoea patients. Although the exact cause still remains an 
enigma, further research in this area may elucidate the exact pathogenesis and 
role of epithelial-derived chimeric cells in morphoea
51
.  
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ROLE OF AUTOANTIBODIES       
 
          The association of morphoea with autoimmune diseases ranges from 
2% to 30% in various case reports published till now. Diseases such as 
Graves disease, vitiligo, type 1 diabetes mellitus, chronic GVHD, Idiopathic 
thrombocytopenic purpura and ulcerative colitis have been reported to 
coexist
13,52
. However, the prevalence of autoimmune disease observed in 
general public is lower than these values. The reported prevalence of positive 
ANA titers in morphoea patients ranges from 20% to 80%
20,52,53,54
. High 
values of antihistone antibodies, single stranded antibody, RA factor and 
homogenous ANA have also been reported in morphoea patients
54
.  
           
            However, childhood-onset morphoea shows more prevalence of  
antihistone antibodies
53
 whereas  anti single stranded antibodies are seen in 
generalised and linear morphoea. High titres of ANA have been reported to 
occur in juvenile patients with linear morphoea and patients with generalised 
morphoea
54
.  
            The titers have not shown any significant correlation with the course 
or severity of disease
26,52,53,54
. Antitopoisomerase II alpha antibody is also 
found in morphoea especially in generalized morphoea patients
55
. B-cell 
activating factor (BCAF) can also show a rise in morphoea
22
. Diminished 
levels of anti RNP antibodies and antiendothelial cell antibodies have been 
seen in morphoea patients
22,43,56
. Also, anticardiolipin, antinucleosome 
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antibodies, fibrillin 1 antibodies have also been found in localized 
scleroderma patients
22
. Cytotoxicity due to antibodies or complement 
activation may have a role in pathogenesis of morphoea
25
.  
                              
CLINICAL PRESENTATION 
              
Morphoea starts with an active stage presenting as erythematous to 
violaceous patches or plaques. As the lesions progress, the center becomes 
white and sclerotic which is surrounded by a characteristic „liliac ring‟ 
forming the border. After the active stage, sclerotic plaques are seen. Some 
cases show plaques with postinflammatory hyperpigmentation. The excessive 
collagen production damages hair follicles and adnexal structures thereby 
forming hairless plaques which are anhidrotic
25
. Raynaud‟s phenomenon is 
not seen in most cases just like sclerodactyly which are features of systemic 
sclerosis. Very few cases develop systemic sclerosis later in life
7
. Another 
characterstic feature is that face and the acral areas are typically spared 
except in some variants of linear morphoea
15
.  
 
1) CIRCUMSCRIBED MORPHOEA (morphoea en plaque) 
    
  
             Circumscribed morphoea is the commonest type of morphoea 
reported in adults. This diagnosis is entertained when there are less than 3 
discrete indurated plaques mostly seen over the trunk
13,26,52
. It presents as 
round or oval circumscribed indurated areas with a central waxy, ivory colour 
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surrounded by a violaceous halo. The size may vary from less than 1 cm to 
30 cm
15
. It mainly involves the dermis with involvement of the panniculus in 
few cases
57
.   
 
This type is further classified as superficial or deep. The superficial 
subtype is more commonly seen and the extent of involvement is till 
epidermis and dermis. Early lesions show an inflammatory or liliac border. 
The deep subtype (previously called SUBCUTANEOUS MORPHOEA or 
MORPHOEA PROFUNDA) involves the dermis and SC tissues and may 
extend till the muscle beneath. The skin above may be normal, atrophic, or  
indurated and is attached to the deeper tissues beneath which accounts for the  
 
characteristic „bound down‟ feeling. Hypoaesthesia may be seen. Obscure  
 
abdominal pain and migraine may be associated
11
.  
 
                                        
Some patients develop lesions in the pressure associated areas as if 
they are koebnerizing. Women commonly show lesions over breasts but 
nipples are not involved
25
. The natural history is towards resolution and 
softening of lesions over a span of 3 to 5 years but these patients are 
predisposed to develop new lesions in the future
13
. 
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OTHER RELATED VARIANTS 
 
a) GUTTATE MORPHOEA 
 
 
Peterson et al
9
 classified guttate morphoea under plaque morphoea. 
Guttate morphoea most commonly occurs on the upper aspect of the trunk as 
multiple oval lesions that are 2 to 10 mms in diameter. The disease starts with 
a mild erythema which proceeds to minimal induration and pigmentation 
abnormalities
9
. It has been proposed that LSA (white spot disease) and 
guttate morphoea are one and same and these two diseases have a similar 
pathogenesis. 
 
b) NODULAR / KELOIDAL MORPHOEA 
 
 
          Keloidal morphoea (nodular morphoea) is described as presence of 
keloid resembling nodules along with typical morphoea lesions. The nodules 
may be confluent or isolated
9
. In 1894, Unna denominated this condition 
'keloid-like scleroderma'
58
. It has been reported in both localized and 
systemic scleroderma but is more commonly seen in systemic sclerosis
59
. 
However, both keloidal and nodular morphoea are considered as one but few 
reports have documented differences between the two entities. Barzilai et al
60
 
stated that the term  keloidal  morphoea includes those cases which have both 
clinical and histological findings consistent with keloid whereas nodular 
scleroderma is used for cases which have histological features comparable 
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with scleroderma. It is common in females seen in the 30 to 50 years of age 
group. The dermatohistopathologic examination may show 1) keloid findings 
2) scleroderma findings 3) keloid and scleroderma findings
61
. The cause of 
nodular morphoea is not well known. Acid-fast bacilli and hepatitis C virus 
are the infectious aetiologies proposed for nodular morphoea
62
. A role of 
organic solvents has also been reported. Cutaneous inflammation can also 
contribute in keloid prone individuals.  
        Acrokeratoelastoidosis has been reported to be associated with nodular  
morphoea
63
.
  
 
c) ATROPHODERMA OF PASINI AND PIERINI 
 
The clinical appearance of Pasini and Pierini‟s atrophoderma has been 
compared to „footprints in the snow‟ or „Swiss cheese-like‟ pattern. 
Morphologically, oval or round, soft, blue to pigmented atrophic areas with 
„cliff-drop‟ borders
64
 mostly seen over trunk. Since pronounced inflammatory 
or sclerotic changes are absent, this entity is often considered "burnt-out 
morphoea." It can occur alone or with other morphoea subtypes elsewhere on 
the skin
9
. Lesions are chronic in nature and are present for 10 to 20 years. 
Many authors have considered it as a variant of morphoea
64
.  
The various synonyms used previously for atrophoderma like 
morphoea plana atrophica, morphoea with unusual degree of atrophy further 
supports that atrophoderma was considered under morphoea spectrum in 
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various case reports
64
. The similarities and differences between the two are as 
follows
65,66,67
     
SIMILARITIES WITH MORPHOEA DIFFERENCES FROM MORPHOEA 
Similar to the late stage of morphoea  
 
clinically and histologically.  
 Earlier onset and a longer course and  
 
rare spontaneous involution. 
Indurated areas similar to morphoea   
 
present within lesions. 
Characterstic cliff-drop border which is  
 
absent in morphoea. 
Coexistence of both diseases in the  
 
same patient. 
Atrophy is followed by induration but  
 
opposite in morphoea. 
May progress to systemic scleroderma. Appendageal structures remain intact in  
 
atrophoderma unlike morphoea. 
 
d) BULLOUS MORPHOEA 
 
 Peterson et al
9
 classified bullous morphoea as one of the types but 
bullous lesions can occur in any type of morphoea. The cause for bullous 
lesions relates to dilatation of lymphatics and release of eosinophil mediators 
like major basic protein
68
. Another school of thought is that patients who 
have associated LSA develop blisters. The level of bulla is subepidermal. 
2) LINEAR MORPHOEA 
 
Linear morphoea is most commonly seen in children, although it is 
seen in adults as well
13,20,52
.
 
It follows the lines of Blaschko and mosaicism 
has been the proposed mechanism for this
69
. There have been reports stating 
that bilateral involvement in linear morphoea of children ranges from 5 to 
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25%
13, 26
. Patients usually complain of pain, arthralgia or oedema before the 
onset of the lesions
11
. Clinically, one or more lesions in a linear fashion with 
an inconspicuous liliac ring are seen and show involvement upto the 
underlying bone thereby resulting in deformities, contractures, and severe 
limb atrophy
9
. Linear morphoea involves lower limbs more commonly as 
compared to the upper limbs. Homolateral lesions involving limbs of one side 
of the body have also been documented. Rarely one half of the body may be 
affected. The lesions are seen along the limb or around the trunk, but ainhum 
like lesions have also been reported
70
. Linear morphoea is associated with 
high titres of ANA usually. Hypertrichosis, melorheostosis
 
and dystrophic 
calcinosis cutis are few asssociations of linear morphoea
22
. Keloidal 
morphoea was also seen in a linear fashion in one report
71
. Linear morphoea 
of lower limbs is more commonly associated with spina bifida occulta
11
. The 
subtypes of linear morphoea are en coup de sabre, Parry Romberg syndrome 
and linear limb involvement
25
. 
a) EN COUP DE SABRE (FRONTOPARIETAL LINEAR 
MORPHOEA) 
 
This entity has been so named as the morphology of the lesion 
simulates the depression caused by a duelling stroke from a sword
57
. It 
usually affects the forehead. Associated eye and CNS involvement is also 
seen
25
. En coup de sabre is almost always unilateral, but rarely bilateral cases 
have been reported
72
. The disease initiates with contraction and firmness of 
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the overlying skin which then progresses to the formation of an ivory 
coloured sclerotic plaque lesion with increased pigmentation at the borders. 
Ultimately, a groove in a linear fashion is seen on the frontoparietal area 
which extends into the scalp and results in the formation of a linear alopecic 
patch. This depression may involve the cheek, nose and upper lip extending 
into mouth and gingiva
73
. In some patients, involvement upto chin and neck 
may be seen
22
. There may be invovement of jaw which may lead to dental 
abnormalities. Hemiatrophy of the tongue and hemifacial atrophy may be 
visible in less than a year
22
. Rarely, frontoparietal lesions may be trilinear and 
may follow lines of Blaschko
74
.  
 
Bony abnormalities of skull and EEG changes may be present
22
. 
Neurological abnormalities have been reported with ECDS
75
. Eye 
involvement is also commonly seen
76
. External ocular muscle involvement, 
enophthalmos, fundus changes and vasculitis
 
are some of the ocular 
complications
76
. Iris atrophy on the medial side and loss of upper eyelashes 
were also reported in a patient which exactly followed the line of cutaneous 
lesion
77
. Heterochromia of the iris may also be associated
78
. Eyelid oedema in 
one eye has been reported as the presenting lesion in a case report
79
. 
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b) PROGRESSIVE HEMIFACIAL ATROPHY (PARRY-
ROMBERG SYNDROME) 
 
This disease presents as atrophy of the face on one side. It involves 
the skin and tissue below the forehead but the overlying skin is either not 
involved or minimally affected. It is treated as a severe form of en coup de 
sabre by some authors and hence it is considered as a variant of the head 
subtype of linear morphoea. The associated disorders such as neurological 
abnormalities, teeth and eye changes are also reported in Parry Romberg 
syndrome thereby further supporting the above proposition
80
.  
                    
Less than 10% cases report atrophy of the upper extremity on the same 
side. Unilateral hemiatrophy of full body has also been reported. Tollefson et 
al
81  
did a study on 54 patients with ECDS and progressive hemifacial atrophy 
and found out that these are two times more commonly seen in females as 
compared to males. Tollefson et al
81
 also concluded by considering ECDS 
and progressive hemifacial atrophy as variants of same disorder just like 
other authors. 
 
3) PANSCLEROTIC MORPHOEA 
 
It is an uncommon, severe, mutilating form of morphoea involving the 
dermis, fat, fascia, muscle and even bone, usually starting before the age of 
14 years, although adult-onset cases have been reported
82
. It may develop 
from linear morphoea. Superficial and deep sclerosis mainly affects the trunk, 
 
 
31 
 
limbs, scalp and face but the fingertips and toes are spared
22
. There may be a 
claw deformity of the hands and patients may walk on tiptoe because of 
contracture of the Achilles tendons
22
. Arthralgia and stiffness may be seen 
initially and patient might have intense pain because of cutaneous nerves 
involvement
83
. Raynaud‟s phenomenon is absent, but oesophagus, lungs and 
teeth have been involved in a few cases. Flexion contractures, osteoporosis 
and other bone changes are pretty common. The electromyogram and 
histology of muscle may be abnormal, but creatine phosphokinase is under 
normal limits. Elevation of ESR, hypergammaglobulinaemia and eosinophilia 
are frequent
22
. The disease is progressive showing poor respose to treatment 
and occasionally fatal. These cases, especially those with resultant chronic 
wounds, are at increased risk of squamous cell carcinoma (SCC) of the skin
25
. 
Wollina et al
84
 estimated that 6.7% of patients with pansclerotic morphoea 
develop SCC every year. 
 
4) GENERALISED MORPHOEA 
 
It is characterized by indurated areas of the skin which begin as individual 
plaques, 4 or more in number of size greater than 3 cms. Later on, they merge 
and affect atleast two out of seven sites including head & neck, right lower 
limb, left lower limb, right upper limb, left upper limb, anterior trunk and 
posterior trunk
57
.  
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Similar lesions affecting just one side of the body have also been reported 
and are considered as an extreme variant which has its onset during 
childhood
85
.  
 
According to the study conducted by Christianson et al
11
, generalized 
morphoea is most commonly seen in the 30 to 40 years age group. Also, 
approximately eighty percent of cases have their age of onset between 11  
and 50 years of age
12
. It is more commonly seen in the females. The lesions 
have a predilection for the trunk and newer lesions develop over time along  
with increase in size of the existing plaques. Usually, there is no systemic 
involvement
22
. Mechanical compression is considered as one of the 
aetiological factors. Expressionless face with shiny, brown and indurated skin 
is seen. Mouth opening may be restricted
22
 and thorax abnormalities may lead 
to difficulty in breathing as well. Involvement of intercostal muscles has been 
reported to cause death from respiratory failure
86
. Raynaud‟s phenomenon 
may be present but is not seen in all cases. Bullous, keloidal
 
or nodular
59
 type 
may coexist with generalized morphoea. Acral myofibromas may occur in 
few cases
87
. Contracture of joints, hardening of limb and soreness may be the 
presenting complaints in acute phase of the disease. Joint pains were reported 
in 50% of cases
12
. Chronic lesions for more than 20 years may lead to the 
development of squamous cell carcinoma in few cases and calcinosis cutis 
may be another association
88
. Sick sinus syndrome, necrotizing vasculitis, 
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polymyositis, biliary cirrhosis and fasciitis are some of the other 
associations
22
. The disease usually improves after 3 to 5 years but may last 
for longer periods.  
 
5) MIXED MORPHOEA 
    
Approximately 15% of patients have more than one type of morphoea and 
they are classified under mixed morphoea
13,52
. The sequence, in brackets is 
consistent with predominant presentation in a case {like mixed  
morphoea (pansclerotic-circumscribed)}
57
. 
 
 
EXTRACUTANEOUS INVOLVEMENT AND ASSOCIATIONS 
 
Morphoea is not just a cutaneous disease and it has various 
extracutaneous associations. These are reported to be evident in almost 20% 
of the cases and multiple associations are seen in 4% of cases. A recent study 
of morphoea in 750 children
13
 from Europe showed that almost 25% had 
extracutaneous manifestations with joint manifestations in 47%, CNS in 17%, 
vascular in 9% and eye, gastrointestinal, respiratory, kidney and cardiac 
abnormalities being reported in few cases. CNS involvement consisted of 
seizures, vasculitis, neuropathy, headache and neuroimaging changes. Eye 
involvement showed episcleritis, uveitis, glaucoma, xerophthalmia and 
papilledema. Reflux disease was the most common gastrointestinal 
manifestation. Autoantibodies like ANA and rheumatoid factor showed 
higher values in those cases which had some associated disease.  
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Another study conducted by Guariso et al
89
 showed esophageal 
involvement in 57% of cases. In the study conducted by Christianson et al
11
, 
few patients gave history of Raynaud‟s phenomenon in one hand and 
intermittent recurrent colicky abdominal pain. Spina bifida, presence of six  
lumbar vertebrae, transverse arch prolongation, scoliosis, lumbar segements 
pain, rudimentary rib, kyphosis, cervical rib, torticollis, atrophic clavicle, lack 
of  pectoralis muscle, pelvic contraction, short ulna and deformities of acral 
parts were other associations
11
. Morphoea has also been reported to coexist 
with carpal tunnel syndrome, nephritis, primary biliary cirrhosis, myasthenia 
gravis
22
. Myopathy, osteomyelitis
90
, rheumatoid arthritis
20, crohn‟s disease20, 
hashimoto‟s thyroiditis91, celiac disease20, B cell lymphoma92 are other 
associated diseases. 
 
ASSOCIATED SKIN CONDITIONS 
 
 
Morphoea has been reported to occur with warty, vascular or 
pigmented nevi, café-au-lait macules, alopecia areata, generalised ichthyosis, 
dystrophic nails, hirsutism
22
, vitiligo
93
, discoid lupus erythematosus
94
, mixed 
connective tissue disease
95
, eosinophilic fasciitis, becker‟s melanosis96, 
sclerotic panatrophy with disseminated granuloma annulare
22
, systemic lupus 
erythematosus
97
, dermatomyositis
22
, pemphigus
22
, localized bullous 
pemphigoid with subcorneal pustulosis
22
, elastosis perforans serpiginosa
22
, 
lichen sclerosus et atrophicus
98
, psoriasis
20
, oral submucous fibrosis, 
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pigmented purpuric dermatosis and lichen planus
98
. Systemic sclerosis 
patients can have coexisting plaques of morphoea in few cases
99
. There have 
been reports of morphoea progressing to systemic sclerosis in the past
11,14
. 
Chronic and long standing lesions can undergo malignant transformation like 
squamous cell carcinoma
84
 and in sometimes in patients managed with 
azathioprine
100
. 
 
INVESTIGATIONS 
 
BLOOD INVESTIGATIONS 
 
    Anaemia may be seen in morphoea and a case of linear scleroderma 
was reported with autoimmune haemolytic anaemia as well
101
. Blood 
eosinophilia (> 300 cells/mm
3
 or more than 6%) has been reported in 7 % to 
50% of cases with morphoea with study conducted by Marzano et al
16
 on 239 
cases showing 7 % of the patients having eosinophilia whereas the studies 
conducted by Christen-Zaech et al
20
 on 136 children and Zulian et al
13
 on 750 
children showing 18 % of cases with raised levels of eosinophils in blood. 
Blood eosinophilia was seen in 50% of patients in a study conducted by 
Falanga et al
102
. Eosinophilia was more commonly seen in patients with 
linear and generalised morphoea
20,102
. The levels of eosinophilia correlated 
with the disease activity with declining levels coinciding with decrease in 
activity of skin lesions
102
. ESR and CRP may also be raised
13,16
. Zulian et al
13
 
documented 22.2% of linear morphoea children with raised ESR. 
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Thrombocytopenia was also seen in 2 cases
103
. Hypergammaglobulinemia 
with elevated polyclonal IgM and IgG occurs in almost 50% of patients with 
severe skin disease and is more common during clinical progression
6
. 
Complement levels are usually normal, but a C2 complement deficiency has 
been described to coexist with en coup de sabre. 
 
AUTOANTIBODIES 
 Several auto-antibodies are found in morphoea
57 
including antinuclear 
antibodies (46-80%), anti-ss DNA (50%) and antihistone antibodies (47%). 
Anti ss DNA antibodies are commonly seen in cases with generalized 
morphoea (75%) and linear morphoea (50%). Patients with muscle 
involvement showed increased levels of these antibodies than patients 
without any muscle involvement. Disease activity can be predicted by the 
levels of anti ss DNA in a patient. Falanga et al
102
 reported that anti-ssDNA 
antibodies were frequent in generalized morphoea. Anti-ss-DNA antibodies 
were associated with joint contractures, deformities or more extensive, active 
and long-standing disease
102
. In another study, anti-histone antibodies were 
seen in 47% of cases having localized morphoea and 87% of those with 
generalized morphoea. The titres of anti-histone antibodies also give an idea 
about the number of plaques and the number of sites involved
75
. 
Anticardiolipin antibodies were also reported to be seen in cases with 
generalized type and linear type of morphoea.  
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IgM type of anticardiolipin antibodies was more commonly seen than 
IgG in generalised type
54
. Rheumatoid factor (RF) may be found in 39% of 
patients
6
. IgM type of antibodies are seen in almost 60% of cases and seems 
to correlate with severity of the disease
54,57
. Other antibodies like Scl-70, anti-
centromere, Ro/La etc may indicate presence of systemic disease and such 
cases require regular check-ups for many years. It is still under speculation 
whether these auto-antibodies do really have a prognostic role
13
.
 
Raised 
values of tumor necrosis factor alpha and IL-13 have been seen in morphoea 
patients as these promote fibrosis
57
. In a study conducted by Zulian et al
13
 on 
750 children, ANA was positive in 42%, rheumatoid factor in 16%, 
anticardiolipin antibody in 13%, anti ds DNA in 4%, Scl-70 in 3% and 
anticentromere antibody in 2%. Serum procollagen type 1 carboxy-terminal 
propeptide and type 3 procollagen propeptide have also shown raised values 
in patients with morphoea
104
. 
IMAGING 
 
a) THERMOGRAPHY 
         The activity of a linear scleroderma lesion can be assessed by 
thermography
105
. This technique may detect temperature increase in active 
areas and areas of new lesions. A morphoea lesion is considered as 
thermographically active if its temperature differs by + 0.5Â°C from the 
adjacent area or from the contralateral limb
214
. Martini et al
105
 compared the 
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thermographic assessment with the clinical description of lesions and showed 
that thermography had 92% sensitivity and 68% specificity. 
b) ULTRASOUND 
       High frequency ultrasound shows details of the dermis and subcutaneous  
layers. The 20MHz ultrasound allows determining the depth and extent of  
sclerosis in the affected area and also monitoring the course of the disease
106
. 
In pediatric patients, it may show the loss of subcutaneous fat and muscle, 
increased blood flow and increased ecogenicity due to collagen condensation 
in the dermis. Hyperemia and the increasing ecogenicity seem to point to 
active lesions
107
. The major drawback of ultrasound is that it is an operator-
dependent investigation so results may vary
107
. 
c) RADIOLOGICAL STUDIES 
 
           Radiological examination of skull and limbs may show underlying 
growth arrests. A peculiar condition called melorheostosis of bones howing 
cortical hyperostosis can be seen. Shortening of limbs, indurations of skull 
and other bony abnormalities like sacralization of lumbar vertebra, contracted 
pelvis, rib anomaly, atrophy of clavicle, spina bifida occulta, shortened ulna, 
kyphosis, and scoliosis and bone cysts can be made out
11
. 
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d) MRI 
 
MRI is not only used in cases with CNS involvement but also in deep 
and generalized morphoea to estimate the true depth of soft-tissue 
lesions. In the inflammatory phase, MRI may detect thickening of the 
dermis and infiltration of subcutaneous tissue, fascia and muscle as 
increased signal intensity on short tau inversion recovery (STIR) 
sequences and contrast enhanced T1-weighted images.  
 
When bone is involved, a band like intense signal on T2-weighted and 
contrast-enhanced T1-weighted images are seen
108
. The main drawbacks 
of MRI are the need for sedation in younger cases and the presence of 
possible artifacts. MRI of the brain and skull in patients with en coup de 
sabre and Parry-Romberg syndrome may reveal abnormalities such as 
cortical atrophy, subcortical calcifications, white matter lesions, 
ventricular dilatation, leptomeningeal enhancement, anomalous 
intracranial vasculature and skull atrophy, even in the absence of 
neurological symptoms. 
 
e) ELECTROENCEPHALOGRAM 
 
Dysarrythmias in EEG underlying the lesional skin have been reported 
in frontoparietal morphoea. 
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f) OTHER TECHNIQUES 
These include either laser Doppler flowmetry or laser Doppler 
imaging. A recent study of 41 children showed that morphoea plaques 
showed higher blood flow in comparision to normal areas
109. 
CLINICAL ASSESSMENT 
a) Localized Scleroderma Severity Index (LoSSI) 
 
This index (LoSSI) is calculated on the basis of three parameters 
including extension of lesion, inflammation intensity and 
development of new lesions. 14 anatomic areas are examined and 
each area is divided into 3 segments. The score ranges from 0 to 
168
110
.  
                          
b) Computerized skin score (CSS) 
 
This scoring requires the use of a computer software for 
comparing a single lesion over a span of time. It mainly separates 
hyperemic and indurated borders of plaques on a transparent film with 
different colours which is then transferred over a cardboard and 
scanned
111
. 
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c) DUROMETER 
 
It is a handheld instrument for measuring skin induration. The 
reading is based on factors including edema, site, sex and age of the 
patient. Seyger et al
112
 found that although durometer findings showed 
less intra and interobserver variations but on comparing these 
measurements with clinical scores, a difference was noted. 
 
d) CUTOMETER 
 
A cutometer also requires a computer software and basically 
measures skin elasticity and relaxation. The results are influenced by 
location, age, sex, and edema. It is also a hand held device
113
. 
 
 
ROLE OF TGF-β 1 LEVELS 
 
Recently, values of  transforming growth factor β 1 (TGF β1) in a 
morphoea patient have been found to play a role as a disease activity marker 
but this requires further studies and  is an area for future research. The values 
do not depend upon the type of clinical morphoea
114
. 
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HISTOPATHOLOGICAL FINDINGS 
 
There is not much difference in the biopsy findings of the various types 
of morphoea but they differ according to their depth of involvement. Ideally, 
a biopsy sample for morphoea should include tissue upto the level of subcutis 
as the pathology mainly involves the reticular dermis and the subcutis
115
. A 
deep punch biopsy is usually taken for circumscribed morphoea while an 
incisional biopsy is ideal for the other types
116
. Three main stages exist- Early 
inflammatory, intermediate, and late sclerotic. 
 
The epidermis may be normal, atrophic or sometimes slightly thicker 
than usual
22
.  
 
EARLY STAGE 
 
In the early inflammatory stage, found particularly at the violaceous 
border of enlarging lesions, the reticular dermis shows interstitial 
lymphoplasmacytic infiltrates among slightly thickened collagen bundles
115
. 
Vascular changes in the early inflammatory stage generally are mild both in 
the dermis and in the subcutaneous tissue. They may consist of endothelial 
swelling and edema of the walls of the vessels. 
  
INTERMEDIATE STAGE 
 
In the intermediate stage, the inflammatory infiltrates surround eccrine 
coils and are associated with hypocellular collagen bundles and reduced 
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numbers of surrounding adipocytes. A much more pronounced inflammatory 
infiltrate than that seen in the dermis often involves the subcutaneous fat and 
extends upward toward the eccrine glands. Trabeculae subdividing the 
subcutaneous fat are thickened because of the presence of an inflammatory 
infiltrate and deposition of new collagen. Large areas of subcutaneous fat are 
replaced by newly formed collagen, which is composed of fine, wavy fibers, 
rather than of bundles, and which stains only faintly with hematoxylin-
eosin
117
. 
 
LATE SCLEROTIC STAGE 
  
In late stage, as seen in the center of the old lesions, a square 
appearance is seen in the punch biopsy. The epidermis appears normal and 
the inflammatory infiltrate disappears completely except in few areas of 
subcutis. In the papillary dermis, the collagen bundles appear homogenous 
whereas in the reticular dermis they appear thickened, closely packed, and 
hypocellular, and stain more deeply eosinophilic than in normal skin. The 
eccrine glands appear markedly atrophic, appear surrounded by newly 
formed collagen and lie higher in the dermis as a result of the replacement of 
most of the subcutaneous fat by newly formed collagen. The collagen 
consists of thick, pale, sclerotic, homogeneous, or hyalinised bundles with 
only few fibroblasts thereby having a typical homogenous, hyalinised and 
hypocellular appearance
115
. There is paucity of blood vessels with narrowed 
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lumen and fibrotic walls and elastic stains show thick elastic fibers arranged 
in parallel to hypocellular collagen strands and in parallel to the epidermal 
surface. 
BIOPSY FINDINGS IN DIFFERENT TYPES OF MORPHOEA 
 
A) GUTTATE MORPHOEA 
 
         The changes are more superficial with less collagen sclerosis but with  
 
         subepidermal edema. 
 
 
B) LINEAR MORPHOEA 
 
       Linear lesions may show a deeper and more diffuse inflammatory cell  
 
infiltrate extending into the underlying muscle. Vascular changes are 
usually prominent. Ossification of the dermis has been recorded
118
. 
 
C) GENERALISED MORPHOEA 
 
  Initial stages show a lymphohistioplasmocytic inflammatory 
infiltrate in the subcutis. Late stages are characterized by hyalinised 
connective tissue which is responsible for the indurated skin
22
. 
 
D) CIRCUMSCRIBED MORPHOEA 
 
1) SUPERFICIAL VARIANT 
 
The collagen deposition and inflammation are restricted to the 
superficial dermis
119
. A mild lymphoplasmacytic infiltrate surrounds eccrine 
 
 
45 
 
ducts in the superficial dermis. Dermal elastic fibers are not appreciably 
diminished, but there is some loss of CD34-positive spindle cells
119
. 
 
2) DEEP VARIANT 
 
There is thickening and hyalinisation of collagen in the deep dermis 
and in the septa and fascia. There is a mixed inflammatory cell infiltrate 
which includes some multinucleate giant cells. Lipomembranous 
(membranocystic) changes may be present. There may be marked fibrosis in 
the subcutis
120
. Vacuolation of the muscle fibres and interspersed edema 
thereby separating them along with focal inflammatory cells infiltrate are the 
other findings. 
 
E) KELOIDAL MORPHOEA 
 
There are hyalinised thick collagen bundles associated with an increase 
in fibroblasts and mucin
121
. 
 
F) BULLOUS MORPHOEA 
 
       Subepidermal edema with dilated lymphatics in the underlying dermis.  
 
       Erythrocytes are often present in the blister
68
. 
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DIRECT IMMUNOFLUORESCENCE 
 
 Immunofluorescence is usually negative in the lesions of localized 
scleroderma but it may show IgM deposition in the basement membrane and 
IgM and C3 deposition in blood vessels of dermis in one third of the cases of 
generalised morphoea and in few cases of linear morphoea
22
. 
ELECTRON MICROSCOPY 
There is disarray and variable thickness of collagen at the advancing 
border
122
. Endothelial cells in blood vessels contain vacuoles and there is 
widening of the gap between the cells. Collagen fibrils in the subcutis have a 
reduced diameter. 
 
HISTOCHEMISTRY 
 
 Subcutis shows only weak birefringence and trichrome staining and 
there is an increased number of fibroblasts. However, the collagen in the 
subcutis stains strongly with the PAS stain in contrast to the very weak 
staining of that in the dermis. Mucopolysaccharides are present in the early 
lesions, particularly in the subcutis. A study of glycosaminoglycans in normal 
and sclerodermatous skin has shown an increase in hyaluronic acid and 
altered dermatan sulphate in involved skin. Chemical analysis shows 
increased hexosamines and hexoses bound to collagen fibres. Sugars attached 
to the collagen give the homogenous appearance in eosin- haematoxylin 
stain. Immunohistochemistry studies have shown that morphoea mainly 
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shows foci of intercollagenous staining for connective tissue antigens in 
lower part of dermis
242
, and that there is a reduction in the size and number of 
dermal papillae, with increased angiogenesis in the early inflamatory stage 
and various numbers of enlarged vessels in inactive lesions. A further study 
has reported an increase in dermal microvascular pericytes in the peripheral 
zones of active lesions, supporting the concept of a vascular pathogenesis of 
scleroderma
123
. 
 
Immunohistochemical characterization of the infiltrate has shown the 
presence of T lymphocytes of both CD4 and CD8 subtype, as well as 
Langerhans cells and natural killer cells
124
. 
 
 
PROGNOSIS 
 
The expected natural history in morphoea is that of spontaneous 
resolution. Circumscribed morphoea usually resolves over 3 to 5 years
116
.  
Pigmentation is evident for many years in almost 33% of cases. Linear 
morphoea has a longer course as compared to circumscribed morphoea but 
severity decreases with time
22
. Morbid features are more commonly seen 
with linear and deep morphoea and include contractures, limb length 
abnormalities, calcinosis and atrophy of the face
116
. Torok and Ablonczy 
reported that most of lesions healed without any disability
125
. Morphoea cases 
have been rarely reported to progress to systemic sclerosis, prevalence 
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ranging from 1 to 6% according to one case report
126
 and the presence of anti-
Ku antibody may indicate such transformation
127
. Generalised morphoea 
patients show mild improvement over a span of 3 to 5 years, but there have 
been reports stating active disease 33 years after diagnosis
11
 and another 
patient died of bronchiolitis obliterans organizing pneumonia
128
. 
TREATMENT 
 
Usually the disease has a spontaneous resolution and it is not treated if 
there are no associated complications
22
. Treatment usually targets 
inflammatory activity in the early stages as once the disease progresses to the 
sclerosis stage, treatment is not of that much benefit
116
.  
 
   Various topical measures like potent or superpotent topical steroids
129
, 
0.005% calcipotriene, 0.1 % tacrolimus
130
 and 5% imiquimod 
131
 cream have 
been used. Intralesional steroids (triamcinolone acetonide, 5-10 mg/ml) have 
also been found to be helpful
129
. Topical photodynamic therapy has also been 
tried. 
 
Systemic therapy used in morphoea includes phenytoin, p-
aminobenzoate, griseofulvin, penicillin, etretinate, ciclosporin, vitamin D, 
vitamin E, chloroquine and hydroxychloroquine
22
. Regression of plaques of 
morphoea after tamoxifen therapy has also been reported
22
. Oral endothelin 
receptor antagonist bosentan was also found to be useful
22
. d-Penicillamine 
with or without pyridoxine is another modality which has been tried
22
.  
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Methotrexate (15 mg/wk) has been used alone or with daily oral or 
pulsed high dose intravenous methyl prednisolone (1000 mg for 3 days 
monthly). Systemic corticosteroids (1- 2 mg/kg/day) have been found to be 
helpful
132
, although they are effective only in the early inflammatory sages of 
morphoea. 
 
 Phototherapy might inhibit the sclerosing processes and play a role in 
skin softening. Several modalities like systemic and bath PUVA, UVA1, 
narrowband UVB therapy and extracorporeal photochemotherapy have also 
been tried
133
.  
Plasmapheresis (along with systemic steroids) has been reported to be  
 
helpful
134
. 
 
Physical therapy such as physiotherapy may be used to prevent 
deformities and contractures. In few cases, surgeries for contracture relief, 
limb lengthening and deformity correction have been found useful. Even 
plastic surgeons have played a role in cases with ECDS and those with 
ossification. Ulcers associated with bullous lesions have been treated with  
„tissue engineered‟ skin.  
 
  
 
 
 
 
 
 
 
50 
 
 
AIM OF THE STUDY 
 
 
1) To study the clinico-epidemiological features of morphoea and its  
various types. 
2) To study the precipitating factors and other associated diseases. 
3) To correlate the histopathological findings with the stage and various  
types of morphoea. 
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MATERIALS AND METHODS 
 
 
This study was conducted in the Outpatient Department of Government 
Rajaji Hospital, Madurai during the period October 2010 to September 2012 
(24 months). 
 
 
INCLUSION CRITERIA 
 
All consenting patients having 
 
1) Lesions with clinical morphology consistent with morphoea. 
 
2) Lesions which showed histopathological findings consistent with  
 
morphoea inspite of a diagnostic dilemma clinically. 
 
 
EXCLUSION CRITERIA 
 
1) Patients not willing to give consent for examination and biopsy. 
 
2) Patients with lesions where diagnosis was a dilemma clinically and  
   
    biopsy could not be performed due to various reasons. 
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All the patients attending the outpatient department of Dermatology,  
Government Rajaji Hospital were screened during the study period between 
October 2010 and September 2012 and patients satisfying the above 
mentioned criteria were enrolled in the study. After getting their informed 
consent, a detailed history was taken and a thorough dermatological and 
systemic examination was done. 
 
The parameters studied were the age of onset, duration of lesions, sex, 
site, type of morphoea, side of involvement, symptoms, precipitating factors, 
evolution/ regression of lesions, past history, family history, birth history, 
number of lesions, sensation, contractures and associations. Histopatholgical 
examination was done for all the patients. Biopsy was taken from both the 
advancing edge as well as the centre for few cases and from any one site for 
rest. Relevant investigations like blood examination (complete haemogram, 
peripheral smear, renal function tests, blood sugar, liver function tests) and 
urine routine were done for all the cases. Investigations like ANA, 
radiological examination of chest, local part and spine were done for selected 
cases. Opinion of Neurologist and Ophthalmologist were obtained in patients 
of frontoparietal morphoea.  All the data was further compiled and inferences 
were drawn. 
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OBSERVATIONS AND RESULTS 
 
 
In this study, 54 cases of morphoea were encountered in the outpatient 
department of Dermatology, Government Rajaji hospital, Madurai during a 
study period of two years. The following observations were noted. 
 
 
INCIDENCE 
  
The total number of patients who attended the Skin O.P during the 
study period were 106368. The number  of patients diagnosed with morphoea 
were 54 so the overall incidence of morphoea was found to be 0.5 per 1000 
dermatology cases. (Table 1) 
 
               TABLE 1- INCIDENCE OF MORPHOEA 
 
Total number of patients attending Skin 
O.P 
106368 
Patients diagnosed with morphoea 54 
Incidence per 1000 cases 0.5 
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TYPES OF MORPHOEA 
 
Out of the encountered 54 cases, circumscribed type of morphoea was 
the commonest with 28 (51.8%) cases followed by linear morphoea 
(including both limb and head variant) with 15 (27.8%) cases, generalised 
type with 5 (9.25%) cases, pansclerotic type with 3 (5.55%) cases and  mixed 
type with 2 cases  in the descending order. One case of keloidal morphoea 
was also seen. (Table 2, Figure1)  
                         
TABLE 2- TYPES OF MORPHOEA 
 
 
Out of the 15 cases of linear morphoea, 27 % were classified under 
head variant and 73 % under trunk limb variant. (Table 3, Figure 2) 
             
 
 
   TYPES OF MORPHOEA  NO. OF CASES PERCENTAGE 
CIRCUMSCRIBED TYPE         28     51.8% 
LINEAR TYPE ( HEAD VARIANT 
AND TRUNK/LIMB VARIANT) 
        15     27.8% 
MIXED VARIANT TYPE           2       3.7% 
GENERALISED TYPE           5       9.25% 
PANSCLEROTIC TYPE           3       5.55% 
OTHER TYPES (KELOIDAL)           1       1.8% 
TOTAL         54     100% 
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TABLE 3- TYPES OF LINEAR MORPHOEA 
 
SEX RATIO   
In our study 14 cases (26%) were males and 40 cases (74%) were 
females, the overall female: male ratio being 2.85:1. (Table 4, Figure 3,4) 
TABLE 4- SEX RATIO 
CLINICAL TYPES  MALE FEMALE TOTAL 
CIRCUMSCRIBED TYPE      6      22      28 
LINEAR TYPE      5      10      15 
MIXED TYPE      1        1        2 
GENERALISED TYPE      0        5        5 
PANSCLEROTIC TYPE      2        1        3 
OTHERS      0        1        1 
TOTAL     14      40       54 
 
 
 
 
TYPES OF LINEAR MORPHOEA NUMBER OF CASES 
HEAD VARIANT 
 
a) En coup de sabre 
b) Progressive hemifacial atrophy 
 
4 
 
3 
1 
TRUNK LIMB VARIANT 11 
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SIDE-WISE DISTRIBUTION 
 Overall, both sides were involved in maximum number of cases with 
39% of the patients followed by right side involvement with 37% of the cases 
and left side involvement constituting 24%. The right side involvement 
dominated in the individual types with the exception of pansclerotic and 
generalised morphoea where both sides were more commonly involved. 
(Table 5, Figure 5,6) 
TABLE 5- SIDE WISE DISTRIBUTION 
CLINICAL TYPES RIGHT LEFT BOTH 
CIRCUMSCRIBED TYPE 11 9 8 
LINEAR TYPE 7 3 5 
MIXED TYPE 1 1 0 
GENERALISED TYPE 0 0 5 
PANSCLEROTIC TYPE 1 0 2 
OTHERS 0 0 1 
TOTAL 20 13 21 
 
AGE OF ONSET 
          In our study, the minimum age at onset of the disease was 2 years and 
3 months whereas the maximum age reported was 71 years. Age group 11-20 
years was most commonly involved with 22 (40%) cases. (Table 6, Figure 7) 
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                     TABLE 6- AGE OF ONSET- OVERALL 
 
AGE OF ONSET WISE DISTRIBUTION OF CIRCUMSCRIBED 
TYPE  
The commonest age group involved was 11-20 years with 11(39.5%) cases.  
(Table 7, Figure 8) 
TABLE 7- AGE OF ONSET (CIRCUMSCRIBED TYPE) 
 
 
 
 
 
 
 
 
 
AGE IN 
YEARS 
MALES FEMALES TOTAL PERCENTAGE 
0 – 5 0 4 4 7.5% 
6- 10 3 7 10 18.5% 
11- 20 8 14 22 40% 
21- 30 1 6 7 13.25% 
31- 40 1 3 4 7.5% 
41- 50 0 5 5 9.25% 
> 50 1 1 2 4% 
AGE IN YEARS MALES FEMALES TOTAL 
0 -5 0 4 4 
6- 10 1 5 6 
11- 20 3 8 11 
21- 30 1 1 2 
31- 40 0 1 1 
41- 50 0 2 2 
> 50 1 1 2 
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AGE OF ONSET WISE DISTRIBUTION OF LINEAR TYPE 
The commonest age group involved was 11-20 years with 5 (33.3%) cases.  
(Table 8, Figure 9) 
TABLE 8- AGE OF ONSET (LINEAR TYPE) 
 
 
 
 
 
 
 
 
 
 
 
 
AGE OF ONSET WISE DISTRIBUTION OF GENERALISED TYPE 
The commonest age group involved was 41-50 years with 2 (40%) cases.  
(Table 9, Figure 10) 
 
 
 
 
 
AGE IN 
YEARS 
    MALES  FEMALES TOTAL 
0-5 0 0 0 
6- 10 1 1 2 
11- 20 3 2 5 
21- 30 0 4 4 
31- 40 1 2 3 
41- 50 0 1 1 
> 50 0 0 0 
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TABLE 9- AGE OF ONSET (GENERALISED TYPE) 
 
 
 
 
 
 
 
 
 
 
AGE OF ONSET WISE DISTRIBUTION OF PANSCLEROTIC TYPE 
All the cases occurred in the age group 11-20 years. (Table 10, Figure 11) 
TABLE 10- AGE OF ONSET (PANSCLEROTIC TYPE) 
 
 
 
 
 
 
 
 
 
 
AGE IN 
YEARS 
    MALES  FEMALES TOTAL 
0 – 5 0 0 0 
6- 10 0 1 1 
11- 20 0 1 1 
21- 30 0 1 1 
31- 40 0 0 0 
41- 50 0 2 2 
> 50 0 0 0 
AGE IN 
YEARS 
    MALES  FEMALES TOTAL 
    0 – 5 0 0 0 
6- 10 0 0 0 
11- 20 2 1 3 
21- 30 0 0 0 
31- 40 0 0 0 
41- 50 0 0 0 
> 50 0 0 0 
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AGE OF ONSET WISE DISTRIBUTION OF OTHER TYPES 
Only one case of  keloidal morphoea was seen in the age group 11-20 years. 
AGE OF ONSET WISE DISTRIBUTION OF MIXED TYPE 
One case was seen in 6-10 years age group and other in 11-20 years age 
group 
 
 DURATION OF LESIONS 
The duration of lesions at the time of presentation was in the range of 6 
months - 2 years most commonly with 22 (41%) cases. (Table 11, Figure 12) 
TABLE 11- DURATION OF LESIONS 
 
SITE WISE DISTRIBUTION- TOTAL 
Overall, multiple sites involvement was seen in 25 cases (46%) and 29 
cases (54%) showed single site involvement.  
SINGLE SITE INVOLVEMENT- 29 CASES 
      In cases where only one site was involved, back and lower limbs were the 
most commonly involved sites with 28% cases each. (Table 12, Figure 13) 
DURATION OF 
LESIONS 
MALE FEMALE TOTAL PERCENTAGE 
0-6 mo 7 14 21 39% 
6mo- 2 years 3 19 22 41% 
2-5 years 2 3 5 9% 
>5 years 2 4 6 11% 
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TABLE 12- SITE WISE DISTRIBUTION-SINGLE SITE 
SITE NUMBER OF 
PATIENTS 
PERCENTAGE 
HEAD AND NECK 
a) FOREHEAD AND SCALP 
b) FACE 
c) BOTH 
 
6 
3 
2 
1 
0 
20% 
CHEST 0 - 
BACK 8 28% 
ABDOMEN 1 4% 
UPPER LIMBS 6 20% 
LOWER LIMBS 8 28% 
 
MULTIPLE SITES INVOLVEMENT- 25 CASES 
In multiple sites involvement, upper limbs were most commonly 
involved with 72% of cases. (Table 13, Figure14) 
TABLE 13- SITE WISE DISTRIBUTION- MULTIPLE SITES 
SITE NUMBER OF 
PATIENTS 
PERCENTAGE 
HEAD AND NECK 
a) FOREHEAD AND SCALP 
b) FACE 
 
5 
2 
3 
0 
20% 
             CHEST 6 24% 
             BACK 10 40% 
            ABDOMEN 11 44% 
            UPPER LIMBS 18 72% 
            LOWER LIMBS 13 52% 
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SITE WISE INVOLVEMENT OF CIRCUMSCRIBED TYPE 
 Circumscribed morphoea affected back most commonly in our study  
with 8  cases (28.5%). (Table 14, Figure 15) 
TABLE 14- SITE WISE INVOLVEMENT (CIRCUMSCRIBED TYPE) 
SITE NUMBER OF 
PATIENTS 
PERCENTAGE 
HEAD AND NECK 
a) FOREHEAD 
AND SCALP 
b)  FACE 
 
2 
1 
 
1 
 
7% 
CHEST 0 - 
BACK 8 28.5% 
ABDOMEN 1 3.5% 
UPPER LIMBS 4 14.5% 
LOWER LIMBS 5 18% 
MULTIPLE SITE 
INVOLVEMENT 
8 28.5% 
 
SITE WISE INVOLVEMENT OF LINEAR TYPE 
Multiple site involvement was most common in linear type with 8 
cases (53%).  Within multiple sites involvement, upper limbs were more 
commonly involved with 7 cases as compared to 3 cases where lower limbs 
were involved. (Table 15, Figure 16) 
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TABLE 15- SITE WISE INVOLVEMENT (LINEAR TYPE) 
SITE NUMBER OF 
PATIENTS 
PERCENTAGE 
HEAD AND NECK 
a) FOREHEAD 
AND SCALP 
b)  FACE 
c) BOTH 
 
4 
2 
 
1 
1 
27% 
UPPER LIMBS 1 7% 
LOWER LIMBS 2 13% 
MULTIPLE SITE 
INVOLVEMENT 
8 53% 
 
SITE WISE DISTRIBUTION OF MIXED TYPE 
Multiple sites were involved in both the cases. 
SITE WISE DISTRIBUTION OF PANSCLEROTIC TYPE 
Two cases involved lower limbs as well as upper limbs, out of which 
one involved all the 4 limbs. One female case showed involvement of just 
right lower limb. 
SITE WISE DISTRIBUTION OF GENERALISED TYPE 
Multiple sites were involved in all the 5 cases. 
SITE WISE DISTRIBUTION OF OTHER (KELOIDAL) TYPE 
Right side of chest and left side of abdomen showed keloidal lesion 
over the morphoea plaques. 
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SYMPTOMS 
Although morphoea was mostly asymptomatic (42.6% of cases) but the  
commonest complaint reported was itching in 19 cases (35.2%). (Table 16, 
Figure 17) 
TABLE 16- SYMPTOMS 
COMPLAINTS NO. OF PATIENTS PERCENTAGE 
Nil 23 42.6% 
Itching 19 35.2% 
Discolouration 9 17% 
Disfigurement 4 7.5% 
Arthralgia 4 7.5% 
Headache 3 5.5% 
Raynauds 
phenomenon 
1 1.9% 
 
EVOLUTION OF LESIONS 
43 cases were in the progressing stage, 10 cases showed static lesions 
and 1 case was reported in the regressing stage. (Table 17, Figure 18) 
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TABLE 17- EVOLUTION OF LESIONS 
EVOLUTION OF LESIONS NO. OF PATIENTS PERCENTAGE 
PROGRESSING 43 79.5% 
STATIC 10 18.5% 
REGRESSING 1 2% 
 
PRECIPITATING FACTORS 
Most of the cases in this study did not have any precipitating factors 
but 4 cases gave history of trauma at the site of morphoea whereas 1 patient 
developed the disease while she was pregnant. (Table 18, Figure 19) 
TABLE 18- PRECIPITATING FACTORS 
PRECIPITATING FACTORS NO. OF PATIENTS PERCENTAGE 
Nil 49 90.7% 
Pregnancy 1 1.9% 
Trauma 4 7.4% 
 
PAST AND FAMILY HISTORY 
There was no patient who gave a past history of morphoea and just one 
patient had similar illness in the family with mother having circumscribed 
type of morphoea. 
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BIRTH HISTORY 
In our study, 46 cases (85%) were born out of non consanguineous 
marriage followed by 3
rd
 degree consanguineous marriage with 5 cases          
(9.5%). (Table 19, Figure 20) 
TABLE 19- BIRTH HISTORY 
CONSANGUINITY NUMBER OF 
PATIENTS 
PERCENTAGE 
NON CONSANGUINEOUS 46 85% 
2
ND
 DEGREE 
CONSANGUINEOUS 
3 5.5% 
3
RD
 DEGREE 
CONSANGUINEOUS 
5 9.5% 
 
ASSOCIATED SYSTEMIC DISEASES 
Almost 90% did not have any associated systemic diseases but 
Diabetes mellitus and Hypertension were seen in 3.7% of cases each. (Table 
20, Figure 21) 
TABLE 20- ASSOCIATED SYSTEMIC DISEASES 
ASSOCIATED SYSTEMIC 
DISEASES 
NUMBER OF 
PATIENTS 
PERCENTAGE 
BRONCHIAL ASTHMA 1 1.9% 
DIABETES MELLITUS 2 3.7% 
HYPERTENSION 2 3.7% 
NIL 49 90.7% 
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NUMBER OF LESIONS 
Most of the cases in our study had multiple lesions, 67% to be exact.  
(Table 21, Figure 22) 
TABLE 21- NUMBER OF LESIONS 
NUMBER OF LESIONS NUMBER OF 
PATIENTS 
PERCENTAGE 
SINGLE 18 33.4% 
MULTIPLE 36 66.6% 
 
SENSATION 
Out of the 54 patients, 3 patients had variable loss of sensation over the 
lesions. (Table 22) 
TABLE 22- SENSATION 
 
 
 
 
 
 
 
 
 
 
 
SENSATION NO. OF PATIENTS 
INTACT 51 
VARIABLE LOSS 3 
PERCENTAGE 5.55% 
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CONTRACTURES 
Out of the 54 patients, all 3 patients with pansclerotic morphoea had  
contractures. (Table 23) 
                           TABLE 23- CONTRACTURES 
 
 
HEMIATROPHY 
No. of  patients showing hemiatrophy of tongue- 2. 
No. of  patients showing hemiatrophy of face- 1.  (Table 24, Figure 23) 
TABLE 24- HEMIATROPHY 
TOTAL NUMBER OF PATIENTS 54 
PATIENTS WITH HEMIATROPHY 3 
PERCENTAGE 5.55% 
 
COMPLETE BLOOD COUNT 
10 patients (18.5%) out of 54 showed eosinophilia and 6 patients  
(11%) had anaemia. (Table 25, Figure 24) 
 
 
TOTAL NUMBER OF 
PATIENTS 
54 
PATIENTS WITH 
CONTRACTURES 
3 
PERCENTAGE 5.55% 
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TABLE 25- COMPLETE BLOOD COUNT 
ABNORMALITY NO. OF 
PATIENTS 
PERCENTAGE 
NIL 42 77.8% 
ANAEMIA 6 11% 
EOSINOPHILIA 10 18.5% 
 
LIVER FUNCTION TESTS 
Only one patient with circumscribed morphoea showed abnormal liver 
function tests with raised liver enzymes. 
HISTOPATHOLOGY 
SITE OF BIOPSY 
Biopsy was taken from the centre of the lesion for most of the cases (68.5%).  
(Table 26, Figure 25) 
TABLE 26- SITE OF BIOPSY 
SITE OF BIOPSY NUMBER OF PATIENTS PERCENTAGE 
EDGE 7 13% 
CENTRE 37 68.5% 
BOTH 10 18.5% 
 
         Out of the 44 cases from which biopsy was taken from a single site, 
54.5% of cases were classified as early morphoea and intermediate and late 
stages accounted for 29.5% and 13.5% respectively. 2.5% of cases had 
features of more than one stage. (Table 27, Figure 26) 
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TABLE 27-HISTOPATHOLOGICAL STAGE OF MORPHOEA 
STAGE OF MORPHOEA NUMBER OF 
PATIENTS 
PERCENTAGE 
EARLY STAGE 24 54.5% 
INTERMEDIATE STAGE 13 29.5% 
LATE STAGE 6 13.5% 
OVERLAP OF TWO 
STAGES 
1 2.5% 
 
NAIL CHANGES 
Leukonychia and nail dystrophy were most commonly seen in 3.7 %  
cases. (Table 28, Figure 27) 
TABLE 28- ASSOCIATED NAIL CHANGES 
NAIL CHANGES NO. OF PATIENTS PERCENTAGE 
NIL 49 90.7% 
LEUKONYCHIA 2 3.7% 
MELANONYCHIA 1 1.9% 
NAIL DYSTROPHY 2 3.7% 
 
ASSOCIATED SKIN DISEASES 
The commonest skin disease which was found to be associated was LSA in  
 7.4 % cases. (Table 29, Figure 28) 
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TABLE 29- ASSOCIATED SKIN DISEASES 
DISEASES NO. OF PATIENTS 
NIL 43 
HYPERTROPHIC SCAR 1 
KELOID 1 
PSORIASIS 1 
LICHEN SCLEROSUS ET ATROPHICUS 4 
SEBORRHEIC MELANOSIS 1 
LICHEN STRIATUS 1 
VITILIGO 2 
COLLOID MILIUM 1 
BECKER‟S NEVUS 1 
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DISCUSSION 
We encountered 54 cases of morphoea in this study which was done 
for a span of 2 years.  
INCIDENCE 
Out of a total 106368 cases visiting the dermatology outpatient 
department during the study period, the cases with morphoea were 54 in total. 
Thus the incidence rate of morphoea was 0.5 per 1000 dermatology cases. In 
a study done by Peterson et al
12
 in Olmsted county between 1960-1993 on 82 
cases showed the incidence rate as 0.027 per 1000 population. 
 
INCIDENCE OF VARIOUS CLINICAL TYPES 
 
The incidence of various clinical types of morphoea in our study was 
as follows   
   Circumscribed- 51.8% 
    Linear (Head and trunk/limb variant)- 27.8% 
     
    Generalised- 9.25% 
 
    Pansclerotic- 5.55% 
 
    Mixed- 3.7% 
 
    Other unclassified variants (Keloidal morphoea) - 1.8% 
 
Out of the 15 cases of linear morphoea, 27 % were classified under 
head variant and 73 % under trunk limb variant. 
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Our findings were in concurrence with the study conducted by Peterson et 
al
12
 on 82 cases which reported that 56% of patients had plaque type 
morphoea, 20% linear, 13% generalized and 11% had deep morphoea. A 
study by Christianson et al
11
 of 235 cases showed an incidence of 35% of 
plaque type, and 46% of linear type and 19% of generalized morphoea.  
 
 
SEX RATIO 
 
The overall sex distribution in our study pointed towards a female 
predominance with female to male ratio being 2.85:1. This was found to be 
consistent with studies conducted by Christianson et al
11
 and Peterson et al
12
 
with ratios being 3:1 and 2.6:1 respectively. The individual types of 
morphoea also followed a similar pattern with exception of pansclerotic 
morphoea where males were reported to be more commonly involved. Linear 
morphoea in our study showed a female to male ratio as 2:1 whereas Peterson 
et al
12
 reported an even sex distribution. 
 
 
SIDE DISTRIBUTION 
 
Bilateral involvement was seen in 39% of cases whereas 61% cases 
showed unilateral involvement with right side being involved in 37% of cases 
and left side in 24% of cases. Circumscribed morphoea showed unilateral 
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involvement more commonly with ratio being 2.5:1 as compared to cases 
with bilateral involvement. 
 
Of the linear morphoea cases, head variant was seen more commonly 
on left side but one case of bilateral en coup de sabre was also seen. A similar 
case has been reported in the literature before by Dilley et al
72
. The trunk 
limb variant showed unilateral involvement more commonly with ratio being 
2:1 in comparision to bilateral involvement. Right side was more commonly 
involved. One patient showed involvement of all the four limbs. 
 
Christianson et al
11
 also reported unilateral involvement more 
commonly in linear morphoea with 102 cases as compared to 6 cases with 
bilateral involvement. On the other hand, plaque morphoea was reported 
more commonly showing bilateral involvement with ratio being 3:1 in 
contradiction to our study. 
 
Christen-Zaech et al
20
 in his study on paediatric morphoea on 136 
patients reported that 74% of patients with plaque type showed unilateral 
involvement which was 71% in our study.  
 
Previous reports state that bilateral involvement in linear morphoea of 
children ranges from 5 to 25%
13,20 
which was 33 % in our study. 
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AGE OF ONSET 
 
The youngest child reported to have morphoea in our study was of age 
2 years and 3 months and the maximum age reported was 71 years. 
 
     Christianson et al
11
 reported the extremes of age as 1 year and 76 years. In 
this study, the maximum number of patients were seen in the age group 11 to  
20 years with 40% of cases belonging to this age group whereas in the study 
conducted by Christianson et al
11
, the peak incidence was between 20 to 40 
years with 40 % of cases. The circumscribed type was also seen most 
commonly in the age group 11 to 20 years. In our study, incidence of plaque 
type below 10 years was 40% and between 20 to 50 years was 18%. In 
Christianson‟s study11, incidence of the same below 10 years was 10% and 
between 20 to 50 years was 75 %. 
 
The commonest age group involved in linear morphoea was 11-20 
years with 33.3% cases. In our study, incidence of linear type below 10 years 
was 13% and below 40 years was 93%. Christianson‟s study11 showed 10% 
incidence below 10 years and 75% below 40 years. So this finding supports 
that linear morphoea is more commonly seen in children than adults. 
Peterson et al
12
 reported in his study that 67% of patients were 
diagnosed before 18 years. In our study, this number was 47 %. Generalised 
morphoea was most commonly seen in the age group 41-50 years with 40% 
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cases. In our study, onset occurred in 80% of cases within age group 11 to 50 
years which was in concurrence with the study conducted by Christianson et 
al
11
 which also showed the same 80 %. All three cases of pansclerotic 
morphoea occurred in the age group 11-20 years and there was a case of 
keloidal morphoea which also occurred in the same age group. Out of 3 
pansclerotic cases, 2 had their age of onset before 14 years in our study. This 
was also noted by Holmes et al
82
. 
Both cases of mixed morphoea had their age of onset between 6 to 20 
years of age. 
 
DURATION OF LESION 
 
The maximum number of cases presented with lesions present for 6 
months to 2 years with 41 % cases. 80% of the cases had the lesions for less 
than 2 years. 
 
SITE OF DISTRIBUTION 
 
Overall, single site involvement was seen in 54% of the cases with 
back and lower limbs being the commonest sites involved with 28% of the 
cases each and were closely followed by head/neck and upper limbs with 
20% cases each. In multiple sites involvement, upper limbs were most 
commonly involved with 72% of cases. 
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Circumscribed morphoea affected back most commonly in our study 
with 28.5% cases. Multiple site involvement was most common in linear type 
with 53% cases. Within multiple sites involvement, upper limbs were more 
commonly involved. 
SYMPTOMS 
Most of the cases in our study were asymptomatic with 42.6% cases 
but itching was the most common complaint noticed with 35.2% of cases. 
Christianson et al
11
 in his study on 235 cases reported arthralgia as the 
commonest symptom with 44% of cases whereas in our study only 7.5% of 
the cases had arthralgia. 
One patient also reported with Raynaud‟s phenomenon (2%). 
 
EVOLUTION OF LESIONS 
In this study 79.5% of the patients had lesions which were still 
progressing at the time of presentation, 18.5 % had static lesions and one 
patient reported with regressing lesions. No other study could be found for 
comparision. 
PRECIPITATING FACTORS 
90 % of the cases in our study did not have any precipitating factors 
but trauma preceded the lesions in 7.4% of the cases. One female patient 
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(2%) developed morphoea lesions during pregnancy which was diagnosed as 
linear morphoea later. 
Christianson et al
11
 also reported similar findings with trauma being he 
commonest precipitating factor with 7.4% cases involved. Infections also 
accounted for 7% of cases. Pregnancy was seen as a precipitating factor in 
3% of cases in this study. 
GENETIC INFLUENCE 
One female patient diagnosed as generalised morphoea gave family 
history of morphoea lesions in her mother. Also 15% of the patients in our 
study were born out of consanguineous marriage thereby giving support to 
the studies conducted by DeKeyser F et al
38
, Kuhnl P et al
39
 on the role of 
genetic factors in aetiology of the disease. 
ASSOCIATED SYSTEMIC DISEASES 
Almost 90% did not have any associated systemic diseases but diabetes 
mellitus and hypertension were seen in 3.7% of cases each. One case had 
bronchial asthma as well. Leitenberger JJ et al
52
 on his study on 245 adult and 
pediatric cases reported 2% of cases with diabetes. 
NUMBER OF LESIONS 
Most of the cases in our study had multiple lesions, 67% to be exact. 
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CONTRACTURES AND HEMIATROPHY 
All 3 patients with pansclerotic morphoea reported with contractures. 
One female patient, diagnosed as Parry Romberg syndrome had hemiatrophy 
of face and two male patients with pansclerotic morphoea were found to have 
hemiatrophy of tongue. One female and one male patient with pansclerotic 
morphoea also had atrophy of right lower extremity. 
Christianson et al
11
 reported that atrophy or contracture or both of one 
or more extremities were noted in 11% of the patients which was 6% in our 
study. 
BLOOD INVESTIGATIONS 
18.5% of patients in our study showed eosinophilia. On reviewing the 
literature, eosinophilia has been reported in 7  to 50% of cases with Marzano 
et al
16  
reporting it in 7%
 
, Christen-Zaech et al
20 
and Zulian et al
13
 reporting in 
18% and Falanga et al
102
 found 50% association. So, our findings were 
consistent with Christen-Zaech et al
20 
and Zulian et al
13
.
 
Anaemia was also seen in 11% of patients in our study. 
 
HISTOPATHOLOGY 
 
Biopsy was done for all cases included in the study and the cases were 
classified into early, intermediate and late morphoea according to the 
histopathological findings. Biopsy was taken from the centre of lesion in 
68.5% cases, both the advancing edge as well as the centre for 18.5% cases 
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and just from the edge in 13% cases. Out of the 44 cases in which biopsy was 
taken from a single site either centre or edge, 54.5% of cases were classified 
as early morphoea and intermediate and late stages accounted for 29.5% and 
13.5% respectively. 2.5% of cases had features of more than one stage. Out 
of the 10 cases in which biopsy was done from both edge as well as centre, 9 
cases showed features of early morphoea from the edge whereas centre 
showed features of either intermediate or late morphoea. 
All cases in which biopsy was taken from just the edge (7 cases) 
showed features of early morphoea. 
 
Out of the 37 cases in which biopsy was done from centre, 46% (17) of 
cases showed features of early morphoea, 35% (13) showed features of 
intermediate morphoea, 16% (6) late morphoea and 3% (1) had overlap of 
more than one stage. 
 
On reviewing the duration of lesions for these cases, we observed that 
16 out of 17  cases (94.1%) classified as early morphoea histopathologically 
had lesions for a duration ranging between 1 to 6 months. 
 
 Similarly, 11 out of 13 cases (85%) classified as intermediate 
morphoea histopathologically had lesions for a duration ranging between 6 
months to 2years. 
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All 6 cases (100%) classified as late morphoea histopathologically had 
lesions for more than 2 years. 
Although no previous studies were found in the literature with similar 
findings but there was a definite correlation between the duration of lesions 
and histopathological findings in our study. 
In a female case of circumscribed morphoea, a sub epidermal space 
was seen on histopathological examination.  
In almost all the cases of linear morphoea, an interesting observation 
was made with more extensive inflammatory cell infiltrate extending till 
subcutaneous tissue. 
A case of nodular/keloidal morphoea showed classical 
histopathological findings of keloid and early stage of morphoea. The 
keloidal lesion showed whorled, nodular mass of collagen interspersed with 
fibroblasts and the morphoea lesion showed homogenous, hyalinised, 
hypocellular collagen and high uptake of eccrine glands.  
Biopsy was done for two cases of morphoea from associated lesions 
which clinically resembled Lichen sclerosus et atrophicus and they showed 
the classical histopathological features of LSA. 
 Another case had associated lichenoid lesion and biopsy showed the 
findings of lichen striatus. 
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 One female with pansclerotic morphoea developed psoriasis like 
lesion over the morphoea plaque which was biopsied and showed features 
consistent with psoriasis. 
Epidermis was either normal or atrophic in all the cases. Pigmentation  
of epidermis was observed in 5 cases. 
 
ASSOCIATED SKIN DISEASES 
The commonest skin disease which was found to be associated with 
morphoea in our study was LSA in 7.4 % cases. Other diseases were vitiligo, 
hypertrophic scar, keloid, lichen striatus, psoriasis, seborrheic melanosis, 
colloid milium, becker‟s nevus. There have been reports of association with 
becker‟s nevus96, psoriasis26, LSA11 and vitiligo93 in the literature.                                                       
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SUMMARY 
1. Total number of cases encountered were 54. 
2. Incidence of morphoea was 0.5 in 1000 dermatology cases. 
3. The incidence of various clinical types of morphoea was 
circumscribed- 51.8% , linear (head and trunk/limb variant)- 27.8%,      
generalised- 9.25%, pansclerotic- 5.55%, mixed- 3.7%, other 
unclassified variants (Keloidal morphoea) -1.8% 
4. The female to male sex ratio was 2.85:1. 
5. Right side was more commonly involved than left. 
6. Circumscribed as well as linear morphoea showed unilateral 
involvement more commonly. 
7. A case of bilateral en coup de sabre was reported. 
8. A case of linear morphoea with involvement of all the four limbs was 
reported. 
9. The maximum number of cases was reported in the age group 11 to 20 
years. 
10. Individual types were also seen most commonly in age group 11 to 20 
years except generalised morphoea.  
11. 54% cases showed single site involvement with back and lower limbs 
being most commonly involved. 
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12. Circumscribed morphoea affected back most commonly with 28.5% 
cases. 
13. Multiple site involvement was most common in linear type with 53% 
cases.  
14. Most cases were asymptomatic but when symptomatic, itching was       
the commonest complaint seen in 35.2% cases.  
15. 79.5% of the patients had lesions which were progressing. 
16. Trauma was seen as a precipitating factor in 7.4% cases and     
 pregnancy in a single case. 
17. Family history of morphoea was present in one case. 
18. Diabetes mellitus, Hypertension and Bronchial asthma were the      
 systemic associations reported. 
19. Most of the cases had multiple lesions, 67% to be exact. 
20. All patients with pansclerotic morphoea had contractures. 
21. Hemiatrophy of face was seen in one patient and hemiatrophy of    
 tongue in two cases. 
22. Two patients had atrophy of right lower extremity. 
23. Eosinophilia was seen in 18.5% of patients. 
24. Features of early morphoea were seen in all the cases in which biopsy 
was taken from the edge. 
25. A definite correlation between the duration of lesions and      
histopathological stage of morphoea was also observed. 
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26. A subepidermal space was also seen in the biopsy of one patient. 
 
27. Another interesting observation was that all cases of linear morphoea                
           showed a more extensive and deep infiltrate. 
28. A rare case of nodular/keloidal morphoea showed foci of increased 
fibrosis amidst acellular, hyalinised collagen. 
29. A colocalization of psoriatic lesions over morphoea plaque was seen 
which was confirmed histopathologically. 
30. Other associated skin conditions reported were LSA, vitiligo,  
hypertrophic scar, keloid, psoriasis, lichen striatus, seborrheic 
melanosis, colloid  milium, becker‟s nevus. 
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CONCLUSION 
 
The incidence of morphoea was 0.5 per 1000 dermatology cases, the 
most common type being circumscribed followed by linear, generalised, 
pansclerotic and mixed in the descending order. The disease was more 
common in females with more number of lesions occurring on right side as 
compared to left. The maximum number of cases occurred in younger age 
group with second decade being the commonest. This age distribution held 
good even for individual subtypes of morphoea with the exception of 
generalised type which was seen in the middle aged. Back and lower limbs 
were the commonest sites involved overall. Most of the cases presented 
without any complaints but when symptomatic, itching was the commonest 
complaint. There were no triggering factors in most of the cases but few 
patients gave history of trauma prior to the onset of the lesions. A rare case of 
bilateral en coup de sabre was also reported and a case of linear morphoea 
showed involvement of all the four limbs. Contractures were seen in patients 
with pansclerotic morphoea. Rare findings like hemiatrophy of face and 
tongue were also reported. Atrophy of right lower extremity was also seen in 
two cases. Eosinophilia was the commonest blood abnormality seen. 
Histopathological examination also showed various interesting observations 
in this study. As reported by authors before, the biopsies taken from the edge 
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of the lesion showed the features of early morphoea. Another interesting 
observation was that a definite correlation was seen between the duration of 
lesions and histopathological stage of morphoea though no similar studies 
were found in the literature for comparision and validation of this finding. 
Also, specimens taken from linear morphoea patients showed a more 
extensive and deep inflammatory infiltrate. A rare case of nodular/keloidal 
morphoea showed foci of increased fibrosis amidst acellular, hyalinised 
collagen. Another rare presentation of colocalization of psoriatic lesions over 
morphoea plaque was seen in one case which was confirmed 
histopathologically. Various cutaneous and extracutaneous associations were 
also found in this study.   
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FIGURE 1- TYPES OF MORPHOEA-PERCENTAGE 
 
 
 
 
FIGURE 2- TYPES OF LINEAR MORPHOEA 
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FIGURE 3- SEX RATIO 
 
FIGURE 4- SEX WISE DISTRIBUTION OF DIFFERENT TYPES 
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FIGURE 5- SIDE WISE DISTRIBUTION- TOTAL 
 
FIGURE 6- SIDE WISE DISTRIBUTION IN DIFFERENT TYPES OF 
MORPHOEA 
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FIGURE 7- AGE OF ONSET -OVERALL 
 
 
FIGURE 8- AGE OF ONSET (CIRCUMSCRIBED TYPE) 
 
 
 
FIGURE 9 - AGE OF ONSET (LINEAR TYPE) 
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FIGURE 10- AGE OF ONSET (GENERALISED TYPE) 
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FIGURE 11- AGE OF ONSET (PANSCLEROTIC TYPE) 
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FIGURE 12- DURATION OF LESIONS 
 
 
 
 
 
 
 
 
FIGURE 13- SITE WISE DISTRIBUTION-SINGLE SITE 
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FIGURE 14- SITE WISE DISTRIBUTION- MULTIPLE SITES 
 
 
FIGURE 15- SITE WISE DISTRIBUTION (CIRCUMSCRIBED TYPE) 
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FIGURE 16- SITE WISE DISTRIBUTION (LINEAR TYPE) 
 
 
 
FIGURE 17- SYMPTOMS 
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FIGURE 18- EVOLUTION OF LESIONS 
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FIGURE 19- PRECIPITATING FACTORS 
 
 
 
 
 
 
 
 
FIGURE 20- BIRTH HISTORY 
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FIGURE 21- ASSOCIATED SYSTEMIC DISEASES 
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FIGURE 22- NUMBER OF LESIONS 
 
 
 
 
 
 
 
 
 
FIGURE 23- HEMIATROPHY 
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FIGURE 24- COMPLETE BLOOD COUNT 
 
 
 
FIGURE 25- SITE OF BIOPSY 
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FIGURE 26-HISTOPATHOLOGICAL STAGE OF MORPHOEA 
 
FIGURE 27- ASSOCIATED NAIL CHANGES 
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FIGURE 28- ASSOCIATED SKIN DISEASES 
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CIRCUMSCRIBED MORPHOEA 
 
LINEAR MORPHOEA- EN COUP DE SABRE VARIANT 
 
 
 
105 
 
LINEAR MORPHOEA- TRUNK LIMB VARIANT 
 
PANSCLEROTIC MORPHOEA 
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MIXED VARIANT- LINEAR WITH CIRCUMSCRIBED WITH EN 
COUP DE SABRE 
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GENERALISED MORPHOEA 
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KELOIDAL MORPHOEA 
 
MORPHOEA LESION                                        KELOIDAL 
LESION
 
Circumscribed area of fibrosis amidst hyalinised, 
hypocellular collagen H & E, 10 X  
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 BILATERAL EN COUP DE SABRE 
 
HISTOPATHOLOGY OF LINEAR MORPHOEA SHOWING 
EXTENSIVE AND DEEP INFILTRATE 
H & E, 10 X   
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HEMIATROPHY OF FACE- CASE OF PARRY ROMBERG 
SYNDROME 
 
HYALINISED COLLAGEN AND SPARSE PERIVASCULAR 
INFILTRATE IN THE DERMIS AND SUBCUTIS 
 
      H & E, 10 X   
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PANSCLEROTIC MORPHOEA WITH HEMIATROPHY OF 
TONGUE 
 
PANSCLEROTIC MORPHOEA WITH ATROPHY OF LOWER LIMB 
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COLOCALIZATION OF PSORIASIS OVER MORPHOEA PLAQUE 
IN A   CASE OF PANSCLEROTIC MORPHOEA 
 
OVERLYING EPIDERMIS SHOWING FEATURES OF PSORIASIS 
 
H & E, 10 X   
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CIRCUMSCRIBED MORPHOEA 
 
ASSOCIATED LICHEN STRIATUS IN THE SAME PATIENT 
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LINEAR MORPHOEA- TRUNK LIMB VARIANT 
 
ASSOCIATED LICHEN SCLEROSUS ET ATROPHICUS IN THE 
SAME PATIENT 
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HISTOPATHOLOGY OF LSA LESION 
 
H & E, 10 X 
ASSOCIATED VITILIGO IN A CASE OF LINEAR MORPHOEA 
 
 
 
116 
 
LINEAR MORPHOEA- TRUNK LIMB VARIANT 
 
ASSOCIATED BECKER’S NEVUS IN THE SAME PATIENT 
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EARLY STAGE 
 
Hyalinised hypocellular collagen with sparse perivascular  
infiltrate in upper dermis     H & E, 10 X 
INTERMEDIATE STAGE 
 
Infiltrate extending into subcutis  H & E, 10 X 
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LATE STAGE 
 
Features of classical morphoea with no significant infiltrate 
        H & E, 10 X 
CASE OF CIRCUMSCRIBED MORPHOEA SHOWING FEATURES 
OF EARLY STAGE ALONG WITH A SUBEPIDERMAL SPACE 
 
H & E, 10 X 
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PROFORMA 
 
CASE NO.:     DATE 
NAME- 
AGE/SEX                                         OCCUPATION 
 
ADDRESS 
 
 
 
 PHONE NO- 
 CHIEF COMPLAINTS- 
 
SKIN LESIONS 
DURATION:     AGE OF ONSET:    
SITE 
 Face:                                          Scalp :  
UL                                               LL 
Chest                                           Back of trunk 
Abdomen: Lower/upper              Buttocks                       Genitals 
NO OF LESIONS 
SYMPTOMS 
Asymptomatic             Discolouration            Disfigurement       Itching        
Pain          
 
Deformity 
 
  OTHERS- Arthralgia       Rec colicky abdominal pain          Headache 
 
                    Discolouration on cold exposure            Lumbar pain        
Seizures 
 
   ANY OTHER- 
 
EVOLUTION/REGRESSION 
A)PROGRESSING 
            1) Increase in size 
            2) New lesions 
B) STATIC 
C)REGRESSING 
PRECIPITATING FACTORS 
Trauma 
 Immobilisation 
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 Vaccination    BCG         DPT       MMR 
 Other injections   B12       Vitamin K 
 H/O Herpes zoster 
 H/O Radiotherapy 
 Pregnancy          
Infection  
Exposure to chemicals 
Silicon implants 
Drugs- Penicillamine 
Carbidopa 
Bromocriptine 
Anti epileptic drugs 
 
PAST H/O- 
DM      HT    TB      BA 
     Other skin diseases 
     Others 
 
 FAMILY H/O- 
Similar lesions 
       Other skin lesions 
       Other diseases 
 
TREATMENT H/O: 
 
GENERAL EXAMINATION: 
 
 
 
 
SYSTEMIC EXAMINATION 
   CVS 
    RS 
    CNS 
    P/A 
 
OCULAR EXAMINATION: 
Lid ptosis:  
Enophthalmos 
Heterochromia iris: 
 
MUSCULOSKELETAL EXAMINATION: 
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DERMATOLOGICAL EXAMINATION: 
 
No of lesions    Single        Multiple       Numerous 
Shape                Oval           Round         Linear         Other 
Size 
Border             Well circumscribed               Ill circumscribed 
Colour             Plaque                                   Margin 
Consistency    Indurated                               Non indurated 
Surface            Shiny                                     Hair 
Atrophy 
Sensation 
Attachment to underlying structures              Subcutis                    Muscle                
Bone 
Others 
Tenderness 
SCALP 
 
 
HAIR 
 
 
ORAL CAVITY AND DENTITION 
 
 
 
GENITALIA 
 
 
PALMS AND SOLES 
 
 
NAILS 
 
 
DIAGNOSIS 
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INVESTIGATIONS: 
 
COMPLETE HAEMOGRAM- 
Hb 
TC 
DC 
ESR 
PERIPHERAL SMEAR 
 
BLOOD SUGAR 
                 UREA 
                 CREATININE 
 
LFT 
 
X RAY              LOCAL PART               SPINE 
 
BIOPSY-   
    Date- 
    Site- 
    Early or Late lesion 
 
  Special stain 
 
  Report and number 
 
 
 
 
 
OPHTHALMOLOGY OPINION: 
 
 
 
NEUROLOGY OPINION: 
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KEY TO MASTER CHART 
A   - Anaemia 
Abn   - Abnormal 
Ar  - Arthralgia 
At   - Atrophic 
B   - Both 
BA  - Bronchial asthma 
BN   - Becker‟s nevus 
 C   - Circumscribed  
ce   - Centre 
CM   - Colloid milium 
CM-2  - 2
nd
 degree consanguineous marriage  
CM-3           -         3
rd 
 degree consanguineous marriage 
CO               -          Contractures  
co                 -          Compatible with morphoea  i.e hyalinised, homogenous 
and  
                                 hypocellular collagen with high uptake of eccrine glands 
DC               -           Discolouration  
DFG             -          Disfigurement 
DM              -           Diabetes mellitus 
 E                 -           Eosinophilia 
ear                -           Early 
ear-int           -           Early to intermediate 
ed                 -            Edge 
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F                 -         Female 
 G               -         Generalised 
 H               -          Headache 
 HA-F         -         Present over face 
 HA-T         -         Present over tongue  
HT              -         Hypertension 
HS               -        Hypertrophic scar  
I                  -         Itching 
Infl              -         Infiltrate 
Infl-PA        -         Periadnexal infiltrate  
Infl-PV        -         Perivascular infiltrate 
Infl-PA, PV -         Both periadnexal and perivascular infiltrate 
Int                -         Intermediate 
int-lat  - Intermediate to Late 
 K             - Keloid  
kel   - Compatible with keloid i.e whorled, nodular mass of  
              collagen interspersed with fibroblasts 
 L   - Left  
L(HV-E) - Linear (Head variant- en coup de sabre) 
L(HV-P) - Linear (Head variant- Parry Romberg syndrome)  
L(TL)           -         Linear (Trunk/limb variant) 
LNY             -         Leukonychia 
LS                 -         Lichen striatus 
LSA     -  Lichen sclerosus et atrophicus 
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M   - Male  
M (L-C)       -          Mixed (Linear- Circumscribed) 
MNY            -         Melanonychia 
mo                -          Months 
 Mu              -          Multiple 
n                   -          Normal 
N                  -          Nil 
NA               -          Not applicable 
NCM            -          Non consanguineous marriage 
ND      - Nail dystrophy 
NI          - No infiltrate 
O(K)            -           Others (Keloidal)  
p                  -            Present 
 p-B             -            Present on both sides  
pig               -            Pigmented 
 p-L             -            Present on left side 
p-R              -            Present on right side 
 p-Li            -             Present over limbs 
pr                -              Progressing  
Preg            -              Pregnancy  
p-R              -             Present on right side  
Ps                -          Psoriasis 
PSM    - Pansclerotic 
r  - Regressing 
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 R   - Right  
RP      - Raynaud‟s phenomenon  
s        - Static 
S        - Single 
SEC  - Subepidermal cleft 
SM               -         Seborrheic melanosis 
Tr                 -         Trauma 
 V                 -          Vitiligo 
VL                -          Variable loss 
 y                   -           Years 
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Bindiya 1 C 17 y 7 mo F R p I pr N N NCM N S n N N n n NA ce co int At Infl- PA Infl N N
Pandeeshwari 2 C 49 y 1 mo F B p p I pr N N NCM N M n N N n n NA ce co ear n Infl- PA NI HS N
Muthurathinam 3 C 21 y 1 y F B p I pr N N CM-2 N M n N N n n NA ce co int At Infl- PA Infl N N
Johnson 4 C 51 y 6 mo M L p N pr Tr N NCM N S n N N n n NA a) ed b) ce co a) ear b) int a)n, b) n a) Infl- PV,b) Infl-PA a)NI,b)Infl N N
Kaleeshwari 5 C 12 y 3 mo F B p p I, DC pr N N NCM N M n N N n n NA ce co ear n Infl-PA, PV NI N N
Balaji M.S 6 C 20 y 1 y M R p p H pr N N NCM BA M n N N n n NA ce co int At Infl-PA, PV Infl N N
Ponammal Devi 7 C 47 y  3 y F B p-B p-L N pr N N NCM DM M n N N n n NA ce co int At Infl-PA, PV Infl N N
Kavitha 8 G 7 y 13 y F B p p p-B p-B I pr N N CM-3 N M n N N n n NA a) ed b) ce co a) int b) int a)At,b) At a)Infl- PV, b)Infl- PA a)Infl, b)Infl N N
Priyadarshini 9 G 11 y 3 mo F B p p p-B p-B N pr N p NCM N M n N N n n NA ce co ear n Infl- PV NI N N
Thangaselvi 10 L(TL) 28 y 2 y F B p-B p-L Ar pr Preg N NCM N M n N N n n n ce co ear-int n Infl- PV Infl N N
Seetharaman 11 L(TL) 14 y 6 mo M R p p-R N pr N N NCM N M n N N n n n ce co ear At, pig Infl-PV NI N LNY
Kanimozhi 12 C 20 y 2 mo F R p N pr N N NCM N S n N N n n NA a) ed b) ce co a) ear b) ear a)n, pigb)n a)Infl- PV,PA b) Infl-PV a)NI b) NI N N
Valli 13 G 48 y 2 y F B p p p p-B p-B Ar, H pr N N NCM N M n N N n n NA ce co lat n NI NI K MNY
Saranya 14 C 15 y 1 mo F L p N s N N NCM N M VL N N E n NA ce co ear At Infl-PV, PA NI N N
Satipriya 15 M (L-C) 11 y 6 mo F R p p I pr N N CM- 3 N M n N N n n NA ce co ear n Infl- PA NI N N
Anushya 16 C 12 y 2 mo F R p N pr N N NCM N S n N N A n NA ce co ear At Infl-PV, PA NI N N
Uma 17 PSM 19 y 5 y F R p I s N N NCM N M VL p P-Li n n Co ce co int At, pig  Infl-PA, PV Infl Ps N
Rohini 18 C 6 y 1 y F R p N s N N NCM N S n N N n n NA a)ed b) ce co a) ear b) int a) At b) At a) Infl-PV,PA  b) Infl-PV,PA a) NI b) Infl N N
Mousijan 19 C 7 y 1 mo M R p N pr N N NCM N S n N N E n NA ce co ear At Infl-PV NI N N
Ranji 20 C 10 y 6 mo F B p p-B p-B N pr N N NCM N M n N N E n NA a) ed b) ce co a) ear b) int a)At,b) At a)Infl-PV,b)Infl-PA,PV a)NI b) Infl N N
Praveen kumar 21 L(TL) 10 y 1 y M R p I pr N N NCM N M n N N n n n a) ed b) ce co a) ear b) int a)At b) At a) Infl- PV b) Infl- PV a) NI b) Infl N N
Ramuthai 22 C 7 y 1 y F L p I, H pr Tr N NCM N S n N N A, E n NA ed co ear At Infl-PV, PA NI N N
Prasanthani 23 C 7 y 3 mo F L p N pr N N NCM N S n N N n n NA ce co ear n Infl- PA NI N N
Ramya 24 C 13 y 2 mo F B p-B p-B I pr N N CM-3 N M n N N E n NA a)ed b) ce co a) ear b) ear a) At b) At a) Infl-PV  SEC b) Infl A) NI b) NI N N
Anita 25 C 19 y 1 y F B p-B N pr N N NCM N M n N N n n NA a) ed b)ce co a) ear b) int a) At b) At a) Infl- PV b)Infl- PV a)NI b) Infl N N
Raja 26 L(HV-E) 32 y 1 mo M R p N pr N N NCM N S n N N n n NA ce co ear n Infl- PV NI N N
Seethalaxmi 27 L(TL) 50 y 7 mo F R p Ar pr N N NCM DM M n N N n n n ce co int At Infl- PV Infl N ND
Kritika 28 C 8 y 1 y F L p N s N N NCM N S n N N n n NA ed co ear At Infl- PA NI N N
Utchimahali 29 L(TL) 24 y 5 mo F R p p p I pr N N NCM N M VL N N n n n ce co ear At Infl- PV NI N N
Amrithalaxmi 30 O(K) 19 y 15 mo F B p- R p-L N pr N N NCM N M n N N n n NA a)ce b) ce co a) kel b) ear a) n b) At a) kel b) Infl- PV a)NI b) NI N N
Veeranan 31 C 28 y 4 y M L p p I s N N NCM N M n N N E n NA ed co ear n, pig Infl- PV NI SM N
Velumrugan 32 C 17 y 3 mo M L p N s N N NCM N S n N N n n NA ce co ear At Infl- PV NI N N
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